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Abstract
Streptomyces clavuligerus produces the medicinally important specialized
metabolite clavulanic acid (CA), but detailed understanding of the roles played by many
genes involved in CA biosynthesis is still lacking. These include the overlapping blm
(orf12), orf13 and orf14 genes, disruptions of which cause defective CA production in S.
clavuligerus. I investigated the potential polarity associated with disrupting blm in S.
clavuligerus, along with the cellular localization of Blm.  This was accomplished using
complementation of prepared blm deletion mutants and western analysis of strains
expressing epitope (FLAG) tagged copies of the protein. blm-like genes from other
microorganisms containing sequenced CA gene clusters were examined for their ability to
complement a S. clavuligerus blm in-frame mutant. Results demonstrate that the blm
mutation is not associated with polar effects and that Blm is a cytoplasmic protein,
suggesting that it could either play a regulatory or enzymatic role during CA production
in S. clavuligerus.
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1Chapter 1: Introduction
1.1: The Streptomyces
The Streptomyces are ubiquitous Gram-positive, filamentous bacteria that dwell in
diverse environments such as soil and marine sediments.  Their diverse metabolic
capabilities place the Streptomyces centrally in the environmental carbon and nutrient
cycle as they are responsible for the degradation of insoluble organic material (such as
lignocellulose and chitin) through the action of secreted hydrolytic enzymes (Chater et al.
2010). Streptomyces are unusual among prokaryotes in that they follow a complex
multicellular life cycle, which begins as a single unigenomic spore that grows and
germinates to produce branched substrate mycelia (Chater and Losick 1996).  When
nutritional stress occurs, a process of morphological differentiation is initiated by the
substrate mycelia and aerial hyphae grow upward out of the vegetative mycelial mat.  The
aerial hyphae then begin to coil and septate, leading to the formation of mature
unigenomic spores, which are resistant to many environmental factors, including
desiccation and low nutrient availability (Ensign 1978). Once in a supportive
environment, the spores germinate and the life cycle begins again.
Recently, a new mode of apical mycelial Streptomyces growth was discovered
called ‘exploratory growth’ (Jones et al. 2017).  This process involves the interaction
between S. venezulae and fungi, whereby the latter deplete glucose in the growth medium.
This change causes the S. venezulae colonies to transform into non-branching vegetative
hyphae, which can cross biotic and abiotic surfaces.  Additionally, it was found that this
mode of growth can be communicated to other Streptomyces spp. through signalling
2using Volatile Organic Compounds (VOCs) that affect the growth and exploratory
behaviour of the other bacteria (Jones et al. 2017).
VOCs and other specialized metabolites (aka secondary metabolites) are produced
during the process of physiological differentiation where the bacteria alter their
physiology, which in most cases is coordinated with morphological differentiation
(Chater 1993). Specialized metabolites are generally produced during times of slow or no
growth, as they are nonessential for the growth and survival of the producing organism
under laboratory conditions.  Therefore, they are called specialized metabolites as
opposed to primary metabolites (like amino acids, nucleotides, lipids and carbohydrates)
that are essential for growth and survival.  When placed in their natural environment, the
production of specialized metabolites is important for Streptomycetes as it provides them
with a competitive advantage against competing organisms (Van der Mei et al. 2017).
1.2: Specialized metabolites
Streptomyces produce a variety of structurally diverse specialized metabolites,
mostly during stationary phase (idiophase). Cultures transition from primary growth
phase (trophophase) to idiophase upon sensing nutritional stress (Barrios-González et al.
2003). Therefore, development and specialized metabolism are often coordinated and
linked in Streptomyces. In addition, sometimes specialized metabolite production is
regulated through a negative feedback loop, where the final metabolite inhibits an early
step of its own production pathway (Wang et al. 2009). In general, metabolite production
in Streptomyces is highly regulated by many complex mechanisms (discussed further in
section 1.6) due to the coordination of growth and metabolite production.
3Bacterial specialized metabolites are medically, economically and industrially
important for human society. Some are used as pharmaceuticals and function as
antibiotics, anti-tumour agents, immunosuppressants, etc. (Figure 1.1). Streptomycete
specialized metabolites account for over two-thirds of naturally derived antibiotics in
current use (Challis and Hopwood 2003).  In addition, specialized metabolites produced
by Streptomyces are used in agriculture as plant growth promoters, plant protection agents
(fungicides), and environmentally friendly herbicides/antiparasitics (Barrios-González et
al. 2003). Due to the widespread importance of these metabolites, a vast industry exists
that is involved in metabolite production, strain maintenance and strain improvement.
Bacteria are grown using large batch fermenters to produce specialized
metabolites on an industrial scale. Specialized metabolite production is controlled by
regulating growth conditions such as media, aeration etc. (Ser et al. 2016). Another way
of improving specialized metabolite production is by introducing targeted genetic
modifications to the producer organism, which is referred to as strain improvement
(Barrios-González et al. 2003). As a result, specialized metabolite production is a
growing subject of scientific study because improving production may increase drug
efficacy and availability as well as profit for industry.
1.3: β-lactam antibiotics and their mechanism of action
For over 50 years, β-lactam antibiotics have been one of the most important agents
used in the treatment of bacterial infections (Schmidt 2002).  Their limited toxicity
towards humans and wide range of antibacterial activities make them some of our most
successful medicines (Schmidt 2002).  Currently, β-lactam antibiotics make up over 60%
4Figure 1.1: Secondary metabolites produced by S. clavuligerus.  Shown are the β-lactam antibiotics
(A) isopenicillin N and (B) cephamycin C and the pyrrothine antibiotic (C) holomycin.  The β-
lactamase inhibitor (D) clavulanic acid and the immunosuppressant (E) Tacrolimus (FK-506) are also
shown. (F) depicts the core structure of the 5S clavams with respective side chains represented by R.
The C3 and C5 atoms of the oxazolidine ring are highlighted and represent sites of important
differences between clavulanic acid and the 5S clavams.
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5of the world antibiotic market (Van Boeckel et al. 2014).  Antibiotics in this family all
contain a four-member heterocyclic ring (Figure 1.2) and are further classified based on
their chemical structure, solubility or spectrum of activity. Some members contain a
second ring attached to the β-lactam ring and together the rings form a bicyclic core.  The
β-lactams are classified based on the nature of the second ring found in these molecules.
For example, if they contain a five membered, sulfur-containing ring they are called the
penams, and if there is a six-membered, sulfur-containing ring, they are called the
cephams (Dalhoff et al. 2006).  To this end, β-lactams can be divided into the
monobactam, penam, cephem, clavam or carbapenem groups (Table 1.1)  Many β-
lactams are naturally produced but some of them are chemically modified after
purification and these are called the semi-synthetics.  Presently, the cephalosporins and
broad spectrum, semi-synthetic penicillins account for the greatest usage of antibiotics
worldwide (Van Boeckel et al. 2014).
The cell wall is the target of the β-lactams.  Cell walls in bacteria are comprised of
many components, one of which is peptidoglycan.  Peptidoglycan is made up of glycan
(NAG-NAM) chains that are crosslinked by peptide bridges.  The crosslinking of peptides
is essential for the rigidity and stability of the bacterial cell wall and is carried out by DD-
transpeptidases, which are the targets of the β-lactams.  Therefore, β-lactams target
actively growing cells that are crosslinking their peptidoglycan.  The inhibition of
peptidoglycan synthesis leads to structural defects in the cell wall and ultimately cells
lyse due internal pressure (Andersson et al. 2001).
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Figure 1.2: Chemical structures of currently used natural product (clavulanic acid) and synthetic
(sulbactam and tazobactam) β-lactamase inhibitors containing the β-lactam core.  Clavulanic acid is
produced by the bacterium S. clavuligerus, while the other two are completely synthetic. The mode of
action of all three inhibitors is the same with the β-lactam ring (in red) being the target for β-lactamase
inhibition.
7Table 1.1: Classes of β-lactam antibiotics with commercially relevant examples and the
microorganisms that produce them
Class Antibiotic example Producer organism
Penam Penicillin Penicillium chrysogenum
Cephems
(Cephalosporin/Cephamycin)
Cephamycin C
Penicillium chrysogenum
Streptomyces clavuligerus
Streptomyces lipmanii
Nocardia lactamdurans
Clavam Clavulanic acid
Streptomyces clavuligerus
Streptomyces jumonjinensis
Streptomyces katsurahamanus
Carbapenem Thienamycin Streptomyces cattleya
Monobactam Aztreonam Chromobacterium violaceum
81.4: Resistance, β-lactamases and inhibitors
Resistance to β-lactams has resulted from bacteria evolving to avoid the lethal
action of these metabolites.  There are three primary mechanisms that lead to resistance to
β-lactam antibiotics.  First and foremost is the production of β-lactamase enzymes, which
hydrolyze the β-lactam ring and thereby inactivate the antibiotic (Bush 1989a). The
second mechanism employs efflux systems that actively pump β-lactam antibiotics out of
the cell and thereby prevent their accumulation at the cell wall target site.  A third
mechanism involves mutations in the genes of the DD-transpeptidases that lead to
enzymes that no longer bind to the β-lactam and therefore are not inhibited by it.  This is
a very important mechanism which is responsible for methicillin resistance in
Staphylococcus aureus (MRSA) due to target modification (Walsh 2000). Together,
these primary mechanisms, and the ease in which they are transferred to other bacteria are
responsible for the worldwide epidemic of antibiotic resistance.
β-lactams went into widespread clinical use in the early 1940s but by this time β-
lactamases had already been identified in Escherichia coli, suggesting that they were
going to be a problem (Abraham and Chain 1940). Since then, more than 850 different
types of β-lactamase enzymes have been identified and reported.  β-lactamases can be
classified based on different systems, one of which uses the four molecular classes: A, B,
C and D (Drawz and Bonomo 2010). These enzyme classes are based on amino acid
sequence similarity and catalytic mechanism (Drawz and Bonomo 2010). -lactamases in
classes A, C and D use an active-site serine in the catalytic mechanism leading to the
inactivation of the β-lactam antibiotic (process reviewed in Drawz and Bonomo 2010). In
9contrast, the class B β-lactamases do not use an active-site serine and instead are
metalloenzymes that use metal ions for catalysis (Drawz and Bonomo 2010). This makes
the mechanism of inactivation very different between the two groups of β-lactamases.
Recently, the Gram negative pathogen Klebsiella pneumoniae carrying a class B metallo-
β-lactamase, called New-Delhi Metallo-β-lacatmase (NDM), has been reported to confer
resistance to all classes of β-lactams (Chen et al. 2016).
To overcome β-lactam resistance, two main strategies have been developed
(Andersson et al. 2001). The first is to alter the structure of the β-lactam antibiotic so that
it is no longer recognized by the β-lactamase and therefore is not inactivated.  The other
strategy employs the use of β-lactamase inhibitors along with β-lactam antibiotics.  In this
strategy, the β-lactamase inhibitor inactivates the β-lactamase enzyme so that the β-
lactam antibiotic can inhibit the DD- transpeptidase and cause cell lysis. There are two
classes of β-lactamase inhibitors; one that binds to the enzyme reversibly such as
cephalosporins, monobactams and carbapenems (Drawz and Bonomo 2010) and the other
that binds to the enzyme irreversibly such as CA, Sulbactam and Tazobactam (Figure
1.2), a process known as suicide inhibition.
Sulbactum and Tazobactum are synthetic compounds developed by the
pharmaceutical industry, whereas CA is a natural product produced by Streptomyces
clavuligerus (English et al. 1978; Fisher et al. 1980). Overall, the structures of β-
lactamase inhibitors mimic conventional β-lactam antibiotics.  However, in the case of
CA, an oxygen group is present instead of a sulfur group, and this produces an
oxazolidine ring rather than a thiozolidine ring.  As a result, CA binds irreversibly to the
serine hydroxyl group of the β-lactamase, hence this is why it is called a suicide inhibitor
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as the β-lactamase is inhibited permanently (Drawz and Bonomo 2010). On its own, CA
is a very weak antibiotic (Brown 1986) but when given in combination with another β-
lactam antibiotic (e.g. amoxicillin) it can treat resistant infections. Soon after CA’s
discovery, it became the first clinically used β-lactamase inhibitor, thereby extending the
use of β-lactam antibiotics against otherwise resistant infections (Drawz and Bonomo
2010). In particular, CA actively inhibits most of the class A β-lactamases and the
cloxacillin-hydrolysing enzymes of class D; however, CA is not active against
cephalosporinases of class C and Zn2+ metallo- β-lactamases of class B (Bush 1989a, b).
1.5: Clavulanic acid and S. clavuligerus
Streptomyces clavuligerus is industrially used to produce CA for medicinal use.
In addition to CA, S. clavuligerus also produces several other specialized metabolites
(Figure 1.1) and according to genome mining, has the capability to produce numerous
more (Medema et al. 2010). The initial discovery of S. clavuligerus was a result of its
ability to produce cephamycin C (CEF), and only later on was it found to produce CA
upon subsequent re-examination (Howarth et al. 1976).
In addition to S. clavuligerus, two other organisms, Streptomyces jumonjinensis
(Vidal 1987) and Streptomyces katsurahamanus (Kitano et al. 1978), have been shown to
produce CA.  The genes involved in CA production are clustered together forming the
CA gene cluster, which resides next to the CEF gene cluster on the chromosome, thus
creating a super-cluster of genes involved in β-lactam antibiotic production (Ward and
Hodgson 1993). Recent genome sequences have shown that Streptomyces flavogriseus
and Saccharomonospora viridis have gene clusters resembling the CA gene cluster from
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S. clavuligerus, but they have not been shown to produce CA under laboratory conditions
(Alvarez-Alvarez et al. 2013). While S. flavogriseus is a Streptomyces species, S. viridis
is a member of the Pseudonocardiaceae family, but both are classified as Actinomycetes.
In addition to CA, S. clavuligerus, also produces other clavam metabolites such as
clavam-2-carvoxylate, 2-hydroxymethylclavam, 2-formyloxymethylclavam, and
alanylclavam (Figure 1.1). The clavams are classified together due to the presence of a
five membered oxazolidine ring fused to the four membered β-lactam ring (Figure 1.1).
Within the clavams, CA is unique due to its 3R, 5R stereochemistry (Figure 1.1) and
because of this stereochemistry it can inhibit β-lactamases (Baggaley et al. 1997),
whereas all other 5S clavams have not been shown to exhibit β-lactamase inhibitory
activity.  Although the 5S clavams do not have β-lactamase inhibitory activity, they
display some antibacterial/antifungal properties due to other mechanisms. In addition to
the clavams, S. clavuligerus also produces the industrially important antibiotics CEF and
penicillin N (Figure 1.1), which is an intermediate in the CEF biosynthetic pathway
(Higgens and Kastner 1971; Nagarajan et al. 1971). Both of these antibiotics are
clinically used to treat bacterial infections.
The Streptomyces chromosomes are linear and contain high GC (~72%) content
DNA (Lin et al. 1993).  Each chromosome can be divided into conserved core regions
(containing genes essential for survival) flanked by variable arms (Hopwood 2006). The
S. clavuligerus genome consists of a 6.8 Mb linear chromosome and four self-replicating,
linear plasmids, including a 1.8 Mb mega-plasmid (pSCL4) (Medema et al. 2010; Song et
al. 2010).  This genome was mined for potential specialized metabolite gene clusters and
a total of 48 were found; 25 on the mega plasmid and 23 on the chromosome.  Some of
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these include known antibiotic biosynthetic gene clusters (e.g. CA), while others either
resemble known gene clusters or are completely novel (Medema et al. 2010). Therefore,
S. clavuligerus has the genetic potential to produce many different specialized
metabolites, but only a few are able to be produced under laboratory conditions (Medema
et al. 2010). For now, S. clavuligerus is known to produce five medically important
compounds: a β-lactamase inhibitor (CA), a pyrrothine antibiotic (holomycin), two β-
lactam antibiotics (penicillin N and CEF) and an immunosuppressant (Tacrolimus)
(Figure 1.1).
Nearly all studies on the biosynthesis of the clavams (which includes CA and the
5S clavams) have been conducted in S. clavuligerus (Jensen 2012). S. clavuligerus is
unique among the clavam producing Streptomyces because it can produce both CA and
5S clavams, while all others produce either CA or the 5S clavams only (Jensen 2012).
The genes involved in CA and 5S clavam biosynthesis reside in three unlinked
gene clusters in S. clavuligerus. The “primary” CA gene cluster is the one situated next
to CEF gene cluster as mentioned above (Figure 1.3 A) (Tahlan et al. 2004 a, Ward and
Hodgson 1993).  The second gene cluster, the clavam gene cluster (Figure 1.3 B), is
situated on the S. clavuligerus chromosome and is comprised of genes predominately
involved in 5S clavam production (Tahlan et al. 2007). The third gene cluster, the
paralogue gene cluster (Figure 1.3 C), is located on the pSCL4 mega-plasmid (Medema et
al. 2010) and contains second copies of genes involved in both CA and 5S clavam
biosynthesis (Tahlan et al. 2004a; Tahlan et al. 2004b). Therefore, the genetics of CA-5S
clavam biosynthesis is somewhat complicated involving “cross talk” between
chromosomally encoded and plasmid borne gene clusters in S. clavuligerus.
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Figure 1.3: The three unlinked gene clusters responsible for clavulanic acid and 5S clavam biosynthesis in S. clavuligerus.  Each arrow represents a gene
and points in the direction in which it is transcribed.  The name is located below each gene.  The solid line backbone represents the S. clavuligerus
chromosome. (A) The clavulanic acid gene cluster.  A few genes from the cephamycin C gene cluster that are important for clavulanic acid biosynthesis
are included. (B) The clavam gene cluster. (C) The paralogue gene cluster.
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(Tahlan et al 2004a, Liras et al. 2008).
1.6: Clavulanic acid biosynthesis and its regulation
CA and the 5S clavams share a common biosynthetic pathway up to the
intermediate clavaminic acid, after which the pathway diverges (Figure 1.4) (Ward and
Hodgson 1993, Egan et al. 1997).  The biosynthetic reactions shared by the two
metabolite groups are referred to as the “early stages” of the CA-5S clavam pathway
(Ward and Hodgson 1993).
The biosynthetic pathway leading to CA and the 5S clavam is very different than
the one involved in the formation of the conventional penicillin and cephalosporin family
of antibiotics.  The precursors of the biosynthesis of penicillins and cephalosporins arise
using a non-ribosomal peptide synthetase (Martin 1998); whereas an enzyme called
carboxyethylarginine synthase (CEAS) catalyzes the initiation of the CA-5S clavam
biosynthetic pathway using ʟ-arginine and glyceraldehyde-3-phosphate (Figure 1.4).
The early part of the CA-5S clavam biosynthetic pathway involves the
carboxyethylarginine synthase (ceaS2), beta-lactam synthase (bls), clavaminic acid
synthetase (cas) and proclavaminate amidinohydrolase (pah) gene products leading to the
formation of clavaminic acid (Figure 1.4).  The proteins encoded by these genes have
known functions and are well characterized (entire process is reviewed in Jensen 2012,
Hamed et al. 2013).  The only other proteins in the CA pathway that have known
functions are glycylclavaminic acid synthase (GCAS) and clavaldehyde dehydrogenase
(CAD) (Figure 1.4).  GCAS is the first enzyme specifically responsible for the CA arm of
the pathway (Arulanantham et al. 2006) and CAD catalyzes the final step in CA
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Figure 1.4: Schematic of the currently proposed biosynthetic pathway leading to clavulanic acid and
5S clavam production in S. clavuligerus.  Names of intermediates are given under the corresponding
structure and involved enzymes are in bold above corresponding arrows. Question marks represent
unknown enzymes that catalyze multiple reactions leading to the respective metabolite.
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biosynthesis (Perez-Redondo et al. 1998). There are numerous genes from the CA gene
cluster that have not been assigned functions (Figure 1.3 and 1.4), but it has been shown
that knocking each of them out leads to loss of CA production (Jensen et al. 2000, Jensen
et al. 2004, Li et al. 2000, Mellado et al. 2002, Song et al. 2009). Further study is
required to elucidate the function of all genes essential to the CA production pathway.
There are number of regulatory proteins and factors involved in regulating
specialized metabolite production in S. clavuligerus (Jensen 2012). There are two
regulatory genes with known functions from the CEF and CA super-cluster.  CcaR
(cephamycin and clavulanic acid regulator) is present in the CEF arm of the CEF and CA
super-cluster (Figure 1.3 A) and encodes the cluster situated regulator (CSR).  It regulates
the production of both CEF and CA but not the 5S clavams (Perez-Llarena et al. 1997).
In the case of the regulation of CA, CcaR regulates the transcription of claR, which is a
pathway specific regulator required only for the biosynthesis of CA (Paradkar et al.
1998). CcaR also directly regulates the early genes (ceaS2, bls2, pah2 and cas2) involved
in the formation of CA and the 5S clavams as well as its own transcription by binding its
promoter region (Santamarta et al. 2002). ClaR is encoded by a gene found within the
CA gene cluster (Figure 1.3 A) and it regulates the transcription of a few genes (oppA1,
cad and cyp) involved in the late stages of CA biosynthesis but not the genes involved in
the biosynthesis of the 5S clavams (Paradkar et al. 1998).
Multiple systems of global genetic regulation control CA and 5S clavam
biosynthesis.  One such system, the BldA system is quite complex in S. clavuligerus and
possesses several unique features.  The bldA gene encodes a leucine tRNA that recognizes
UUA codons (Guthrie and Chater 1990).  TTA codons are rare because S. clavuligerus
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has high GC content (72%) DNA, therefore not many T or A codons are present.  TTA
codons are found mostly in non-essential genes involved in differentiation and specialized
metabolism. As a result, bldA mutants cannot undergo differentiation (resulting in “bald”
colonies) or specialized metabolite production (reviewed in Hackl and Bechthold 2015).
bldA mutants still produce normal levels of CEF and CA even though CcaR, the CSR of
CEF and CA, carries a TTA codon (Perez-Llarena et al. 1997). All 5S clavams (except
for alanylclavam) are overproduced in bldA mutants because res1, a gene encoding a 5S
clavam regulator, carries a TTA codon that exhibits bldA dependence (Kwong et al.
2012). These two observations infer that some TTA codon-containing genes are
dependent on bldA while others are not (Trepanier et al. 2002). bldA dependence was
found to be based on the residue immediately following the TTA codon (Trepanier et al.
2002).
Although ccaR expression is not regulated by bldA, its transcription is dependent
on another “bald” gene, bldG (Bignell et al. 2005).  BldG is similar to anti-anti sigma
factors from Bacillus subtilis (Bignell et al. 2000). The bldG homologue in S.
clavuligerus is required for aerial hyphae formation and the production of CEF, CA and
the 5S clavams.  Through the regulation of ccaR, bldG controls the production of CEF
and CA (Bignell et al. 2005). However, bldG must also control another regulator since
ccaR does not regulate 5S clavam production.
Recently, a group of small diffusible extracellular regulators called the γ-
butyrolactones (GBLs) have been under intensive study.  They are produced by several
Streptomyces species to regulate the onset of antibiotic production (Santamarta et al.
2005).  In the cell, butyrolactone receptor proteins (BRPs) are bound to regulatory
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sequences called ARE boxes and usually act as repressors (Onaka et al. 1995; Onaka and
Horiniouchi 1997).  ARE boxes are located upstream from genes that are responsible for
the regulation of specialized metabolite production and differentiation (Kinoshita et al.
1999; Onaka and Horiniouchi 1997). When GBLs are released in the cell, they bind to
BRPs causing the BRPs to disassociate from the ARE boxes, which relieves repression
and triggers antibiotic production (Onaka et al. 1995; Onaka and Horiniouchi 1997). In S.
clavuligerus, there is only one BRP that is encoded on the pSCL4 mega plasmid as scaR
(Kim et al. 2004; Medema et al. 2010).  ScaR has been tied to the regulation of CA and
CEF biosynthesis as both metabolites are overproduced in scaR mutants (Santamarta et
al. 2005).  In addition, an ARE box was found 815 nt upstream of the ccaR transcription
initiation site; further indicating a relationship between CcaR and ScaR (Santamarta et al.
2005). Most likely, ScaR functions as a negative repressor of ccaR gene expression, and
this repression is relieved by the binding of a GBL to ScaR, though the identity of this
GBL remains to be determined (Santamarta et al. 2005).
1.7: Putative genes involved specifically in the biosynthesis of clavulanic acid
How clavaminic acid is converted to clavaldehyde is still not well understood.
Information on this part of the pathway is missing.  Although several genes (oppA1, cyp,
fd, orf12, orf13, orf14, orf16, orf21, orf22 and orf23) have been implicated, there is no
clear role for each (Jensen et al. 2000, Jensen et al. 2004, Li et al. 2000, Mellado et al.
2002, Song et al. 2009). Clavaldehyde has the same 3R, 5R stereochemistry of its
oxazolidine ring as CA, whereas clavaminic acid has the same stereochemistry as the 5S
clavams.  Therefore, there has to be an enzymatic reaction that results in the
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stereochemical ring inversion from clavaminic acid to clavaldehyde.  Recently, it has
been proposed that the protein encoded by orf12 (Figure 1.3) could somehow be involved
in the process of cleaving the oxazolidine ring so that ring inversion takes place (Jensen
2012; Valegard et al. 2013).  Still, the mechanism of this inversion is not well understood.
1.7.1: orf12
As mentioned above, orf12 has been a target of research interest due to its
largely unknown function but possible involvement in ring inversion.  It has been found
that S. clavuligerus orf12 mutants are completely unable to produce CA, thus rendering
Orf12 essential for the production of CA (Li et al. 2000; Jensen et al. 2004).  Orf12 shares
the closest amino acid sequence homology to two hypothetical proteins; one found in S.
flavogriseus (61% identity) and one in S. viridis (51% identity).  It is more distantly
related to uncharacterized serine hydrolases and LpqF lipoproteins in Rhodococcus and
Mycobacterium species with ~35% identity across the majority of these sequences.
Sequence similarity (32% identity) has been found between Orf12 (hereafter called Blm)
and class A β-lactamases such as Spyr1 from Mycobacterium gilvum. However, a β-
lactamase function for Blm is not consistent with its essential role in CA biosynthesis (Li
et al. 2000). Blm’s proposed involvement in ring opening or re-closing (for
sterochemical ring inversion) is similar to the β-lactamase activity of binding and
cleaving the β-lactam ring (Jensen 2012; Valegard et al. 2013).  Nonetheless, this
suggestion is weakened by the fact that Blm only retains one of the necessary β-lactamase
catalytic motifs; the SDN motif (Mellado et al. 2002).
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β-lactamases have four catalytic motifs necessary to their function. The first
motif, common to all class A β-lactamases, is S-T-F-K, where S is the active serine
responsible for the nucleophilic attack on the carbonyl group of the β-lactam ring
(Herzberg and Moult 1987; Meroueh et al. 2005). Within this region, Blm differs from
class A β-lactamases in the second (TA) and third (FY) residues (Valegard et al.
2013).  Nevertheless, during biochemical studies on Blm, the S residue in the first
position was found to act as the nucleophilic catalyst to convert cephalosporin C to
deacetylcephalosporin C (Valegard et al. 2013).  The second catalytic motif is S-D-G,
where the G residue is important for penicillinase activity and an N residue (in place of
G) is important for cephalosporinase activity (Jacob et al. 1990). Analysis of the Blm
amino acid sequence indicated that it contains the latter S-D-N motif (Li et al. 2000). The
third motif, common to class A β-lactamases is E-P-E-L-N, which is replaced with D-P-
E-R-R in Blm.  The first E residue is always found in class A β-lactamases while it is
substituted to a D residue in class C β-lactamases (Lobkovsky et al. 1993).  It has been
demonstrated that the E residue is important for catalysis and the substitution of E with D
increases substrate affinity (Gibson et al. 1990).  The final conserved class A β-lactamase
motif is K-(T or S)-G (Herzberg and Moult 1991).  The K residue is important for
hydrogen bonding and the G residue is important for deacylation (Knox et al. 1993;
Escobar et al. 1994).  In class A β-lactamases, this motif is particularly important for
proper positioning of the substrate during acyl-enzyme formation (Zhang et al. 2007) as it
forms part of an external β pleated sheet near the substrate binding pocket (Matagne et al .
1990).  Blm does not possess any of these residues.  Instead, it has an F-K-A motif, which
does not act similarly to the β-lactamase residues.  Although Blm does not contain all of
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the motifs required for β-lactamase activity, its motifs have the potential for
cephalosporin esterase activity as Blm can hydrolyse the ester group of 3’-O-acetyl
cephalosporins (Valegard et al. 2013).  Regardless, this activity is not believed to be its
essential function but rather low level activity due to substrate similarity (Valegard et al.
2013).  Further investigation is required to determine the activity of this protein.
Recent biochemical and structural studies on Blm have revealed that it is a
monomer consisting of two protein domains: a C-terminal penicillin-binding protein
(PBP)/β-lactamase type fold with highest structural similarity to the class A β-lactamases,
fused to an N-terminal domain with a fold similar to steroid isomerases and polyketide
cyclases (Valegard et al. 2013).  The C-terminal domain did not show β-lactamase or PBP
activity, but did show the low-level esterase activity towards 3’-O- acetyl cephalosporins
and a thioester substrate (Valegard et al. 2013).  Based on this, a few functional
possibilities of Blm in CA production have been proposed. One possibility is that Blm is
involved in the epimerization step during the conversion of clavaminic acid to clavulanic
acid (Jensen 2012, Valegard et al. 2013).  This was proposed because the fold of the N-
terminal domain is related to the structure of steroid isomerases, which upon Blm-CA
binding could lead to epimerization (Valegard et al. 2013).  However, no apparent active
site or conserved catalytic residues analogous to steroid isomerases have been found in
Blm.
Biochemical studies have shown that two molecules of CA bind to one molecule
of Blm (Valegard et al. 2013).  The first molecule of CA binds to the Blm active site,
which is lined with residues from both the N and the C terminal domains.  The other
molecule binds between the two domains.  The first CA molecule is orientated in such a
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way that the carbonyl O of the β- lactam ring is positioned in the opposite direction of the
nucleophilic serine (part of the SXXK motif).  This likely is a reason Blm does not show
any β-lactamase activity.  The second molecule of CA does not form any direct hydrogen
bonds to Blm.  Instead, it binds in a hydrophobic cleft that may act as a “gatekeeper” to
the active site. In summary, CA has been shown to bind Blm; however, the biological
significance of that binding is not well understood.  It is possible that there is only one
active site and the second site binds to a CA precursor or ligand in its native host, S.
clavuligerus. Further study is required to give a more complete description of the
enzymatic mechanism that Blm uses in the biosynthesis of CA and what other proteins in
the CA biosynthetic pathway it may be interacting with.
1.8: blm, orf13 and orf14
DNA sequencing studies have revealed that the stop codon of blm overlaps with
the start codon of the adjacent orf13 gene by 4 bp (Figure 1.5 A; Tahlan unpublished). As
a result, blm and orf13 are transcriptionally coupled (Mellado et al. 2002) and may be
translationally coupled. orf13 is predicted to encode a protein that is similar to amino
acid metabolite efflux pumps, suggesting a role in transporting clavulanic acid out of the
cell (Mellado et al. 2002). In addition, the 3' ends of orf13 and orf14 (encoded on the
opposite DNA strand from orf13) overlap by 50 nt (Figure 1.5 A; Tahlan unpublished),
where orf14 also has an unknown function in CA biosynthesis.  This phenomenon is quite
rare as genes encoded on opposite DNA strands do not overlap normally. In previous
studies, when blm, orf13 or orf14 were disrupted, CA production was severely
compromised (Li et al. 2000, Mellado et al. 2002, Jensen et al. 2004), whereas,
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Figure 1.5: A comparison of blm, orf13 and orf14 from the clavulanic acid biosynthesis pathways of S.
clavuligerus, S. flavogriseus and S. viridis.  Arrows indicate transcriptional direction.  The overlapping and
spacing of genes is not to scale.
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overexpression of blm and orf14 showed a significant increase in CA production
(Mellado et al. 2002).
Due to the transcriptional arrangement of blm, orf13 and orf14, particular attention must
be given to the genetic reading frame when creating knock-out mutants.  All previous
mutants of blm (Li et al. 2000, Jensen et al. 2004), orf13 (Jensen et al. 2004) and orf14
(Mellado et al. 2002, Jensen et al. 2004) were created by inserting an antibiotic resistance
cassette at specific positions within each gene.  These studies showed that the three genes
are essential for CA production. However, it is possible that the blm insertional mutations
also affected the transcription and translation of orf13 and orf14, and thus the observed
effect on CA production in the blm mutants may have been due to polar effects on
expression of the downstream genes. Therefore, there is a need for examining the
phenomenon of transcriptional and translational polarity in the blm mutant to confirm its
role in CA production.
Genome sequencing studies have shown that orthologues of blm, orf13, and orf14
are present in S. flavogriseus and S. viridis in arrangements slightly different than in S.
clavuligerus (Figure 1.5). Each predicted protein has ~60% amino acid identity with its
orthologue in S. clavuligerus, except for Blm from S. viridis, which has a 52% amino acid
identity.  Of particular note, both Orf13 and Blm from S. clavuligerus contain additional
amino acid stretches that are not present in either of the predicted S. flavogriseus and S.
viridis protein sequences.  Transcriptional studies have shown that the late genes from the
CA gene cluster (including blm) are barely expressed in S. flavogriseus (Alvarez-Alvarez
et al. 2013). This lack of expression is likely the reason for the inability of S. flavogriseus
to produce CA, but it is not known if the blm gene from S. flavogriseus has the same
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function as its orthologue from S. clavuligerus.
1.9: Main objectives of this thesis
The complexity of CA biosynthesis in S. clavuligerus is one of the reasons why
this pathway has not yet been completely elucidated.  Several questions still remain
unanswered, including the elusive mechanism behind the stereochemical inversion
leading to the 5R configuration of CA and the function of the “silent” CA gene clusters of
S. flavogriseus and S. viridis. The main goal of this thesis was to verify the role of Blm in
CA biosynthesis, to determine its cellular location, and to determine if the genes from S.
flavogriseus and S. viridis are functionally equivalent to their counterpart from S.
clavuligerus. Two blm mutant strains of S. clavuligerus were prepared and tested in
complementation studies using the blm gene.  One mutant was created to test the
possibility of downstream polar effects due to the overlap present between blm and orf13.
The other mutant, an in-frame blm deletion mutant, was created to investigate the sole
effects of Blm on CA production and whether CA production could be rescued by the
blm-like genes from S. viridis, and S. flavogriseus. It is possible that Blm from S. viridis
and S. flavogriseus is defective, or it may have a different function in the production of
some other related compound. The goals of the cellular localization studies of Blm
provide insight into its possible function since most -lactamases are secreted proteins.
This was accomplished by performing western analysis on cellular and secreted fractions
using FLAG epitope tagged (Hopp et al. 1988) Blm as well as two control proteins with
known cellular locations: CcaR (cytoplasmic) and Blip (secreted).
26
Chapter 2: Materials and Methods
2.1: General procedures and supplies
All solutions and media were prepared using HPLC-grade H2O, and were
sterilized before use by autoclaving or by filter sterilization using 2 μm filters (28145-
481, VWR International, Canada).  Unless stated otherwise, all reagents, antibiotics and
dehydrated media were purchased from Sigma Aldrich Canada, Fisher Scientific Canada
or VWR International.  Aseptic techniques with sterile reagents and glassware were used
while handling and manipulating bacterial cultures.  All centrifugation steps throughout
this study were performed using either an Eppendorf 5424 micro-centrifuge (022620401,
Germany) or a Thermo Scientific Sorvall ST 16 R centrifuge (75004380, USA) using a
TX-400 Swinging Bucket Rotor (75004380), unless otherwise indicated.  Optical
densities (ODs) and nucleic acid concentrations were measured using an Implen p300
NanoPhotometer (Implen GmbH, Germany).  All polymerase chain reactions (PCR) were
conducted using an Eppendorf VapoProtect Mastercycler Pro (950040015, Germany) and
subsequent gel electrophoresis was performed using Thermo Scientific OWL easycast gel
boxes and a VWR International 300V Power Source (100414605).  All restriction
enzymes used in this study were obtained from New England BioLabs (Canada).  Gel
purification steps were conducted using the EZ-10 Spin Column DNA Gel Extraction Kit
(Bio Basic Canada Inc., Canada) and performed according to manufacturer’s instructions
except that 34 μl of 50°C H2O was used to elute the DNA and the column was incubated
at 37°C for 5 minutes before the final centrifugation step.  All E. coli and S. clavuligerus
strains were stored as 20% glycerol stocks at -80°C, and all DNA samples were stored at -
20°C.
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2.2: General E. coli procedures
2.2.1: Maintenance and stock preparation
E. coli liquid cultures were grown at 37°C with 200 rpm shaking for 16-18 hours
in 3-5 ml of Lennox broth (LB) (BP1426500, Thermo Fisher Scientific, USA).  Strains
were maintained on LB agar.  When required, media was supplemented with the
appropriate antibiotics as listed in Table 2.1.  All bacterial strains and plasmids used in
this study are described in Table 2.2.
2.2.2: Cosmid and plasmid DNA isolation
For routine screening purposes, cosmid and plasmid DNA was isolated using a
modified alkaline lysis method (Birnboim and Doly 1979).  An overnight culture (1.5 ml)
was transferred to a 1.5 ml microfuge tube and pelleted by centrifugation at 12,000 rpm
for 30 seconds at room temperature.  The supernatant was discarded and the cell pellet
was re-suspended in 100 μl of ice cold Solution I (50 mM glucose, 25 mM Tris-Cl- pH
8.0, 10 mM ethylenediaminetetracetic acid (EDTA)-pH 8.0).  Next, 200 μl of freshly
prepared Solution II (0.2 N NaOH, 1% w/v SDS) was then added and the tube was gently
inverted 5-7 times.  A total of 150 μl of ice cold Solution III (3 M potassium acetate, 2 M
glacial acetic acid, and topped up with H2O, pH 4.6) was added to the tube before
inverting gently 5-7 times.  The tube was incubated on ice for 5 minutes before
centrifugation at 10,000 rpm for 10 minutes at room temperature.  The resulting
supernatant was then transferred to a new 1.5 ml microfuge tube containing 450 μl of ice
cold 95% ethanol.  The contents were vortexed and incubated on ice for 5 minutes before
centrifugation at 10,000 rpm for 10 minutes at room temperature.  The supernatant was
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Table 2.1: Stock and experimental concentrations of antibiotics used throughout this study
*N/A: Not applicable -the antibiotic was not used with this organism.
Antibiotic
Stock Concentration
(mg/ml)
Experimental Concentration
(μg/ml)
E. coli S. clavuligerus
Ampicillin 100 100 N/A*
Apramycin 50 50 25
Chloramphenicol 34 25 N/A*
Hygromycin 50 50 (liquid broth) and100 (solid media) 200
Kanamycin 50 50 50
Nalidixic Acid 50 40 40
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Table 2.2: Cosmids, plasmids and bacterial strains used in this study
Name Antibiotic concentrationfor selection (μg/ml) Genotype and relevant features Reference
Cosmids
12B8
Ampicillin 100
Kanamycin 50
pWE15 cosmid clone containing blm and surrounding
region from the S. clavuligerus chromosome Jensen et al. 2004
Cloning vectors
pGEMT®-Easy Ampicillin 100 E. coli general cloning vector Promega
pHM11a Hygromycin* Integrative Streptomyces expression vector Motamedi et al. 1995
Plasmids for antibiotic
resistance cassettes
pIJ10700 Hygromycin 50 HygR cassette in pBluescript II KS(+) Gust et al. 2003
pIJ773 Apramycin 50 ApraR cassette in pBluescript II KS(+) Gust et al. 2003
Gene disruption constructs
12B8 Δblm-AP
Apramycin*
Kanamycin 50
12B8 Δblm::apra-oriT cassette (blm mutant cosmid) This study
12B8 Δblm::scar
Ampicillin 100
Kanamycin 50
12B8 Δblm::in-frame scar This study
12B8 Δblm::scar
::Δamp::hygR
Hygromycin*
Kanamycin 50
12B8 Δblm::in-frame scar Δamp::hyg-oriT This study
*Final concentration of this antibiotic used for selection is dependent on the bacterial species- see.
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Complementation/localization
constructs
pH:blmSC Hygromycin* pHM11a with blm from S. clavuligerus This study
pH:blmSF Hygromycin* pHM11a with blm from S. flavogriseus This study
pH:blmSV Hygromycin* pHM11a with blm from S. viridis This study
pH:ccaR-FLAG Hygromycin* pHM11a with ccaR from S. clavuligerus with FLAG tag This study
pH:blm-FLAG Hygromycin* pHM11a with blm from S. clavuligerus with FLAG tag This study
pH:blip-FLAG Hygromycin* pHM11a with blip from S. clavuligerus with FLAG tag This study
E. coli strains
NEB5α N/A DH5α derivative cloning host New England Biolabs
ET12567(pUZ8002) Chloramphenicol 25
Kanamycin 25
DNA methylation deficient host used for conjugation
with S. clavuligerus. pUZ8002 provides DNA transfer
functions
MacNeil et al. 1992
BW25113 (pIJ790) Chloramphenicol 25Kanamycin 50
Host for Redirect PCR targeting system with pIJ790 for λ
RED proteins Gust et al. 2003
DH5α (BT340) Ampicillin 100Chloramphenicol 25 Produces FLP recombinase from BT340 plasmid
Cherepanov and Wackernage
1995
S. clavuligerus strains
ATCC 27064 N/A Wild-type (wt) strain
American Type Culture
Collection
Δblm::apraR Apramycin 25 Δblm::apra-oriT mutant (cassette in opposite orientation
to transcription)
This study
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Δorf12::apra Apramycin 25 Δblm::apra
R mutant (apraR in opposite orientation to
blm) Jensen et al. 2004
Δblm-INF N/A Δblm:: scar in-frame mutant This study
S. flavogriseus and S. viridis
strains (respectively)
ATCC 33331 N/A Wild-type (wt) strain American Type CultureCollection
ATCC 15386 N/A Wild-type (wt) strain American Type CultureCollection
Klebsiella pneumoniae
ATCC 15380 N/A Indicator organism for bioassay experiments Reading and Cole 1977
*Final antibiotic concentration for this item is dependent on the bacterial species- See Table 2.1 for further information.
N/A-either strain is antibiotic sensitive or antibiotics were not used in selection
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discarded and the pellet was washed with 300 μl of ice cold 70% ethanol and centrifuged
at 10,000 rpm for 5 minutes.  Gentle aspiration was used to remove the supernatant before
air drying under a laminar flow hood for 20 minutes.  The clear, dried pellet was re-
suspended in 50 μl of H2O containing 20 μg/ml RNaseA (AC117, Omega Bio-Tek, USA)
before being incubated at 37°C for 20 minutes and stored at -20°C for subsequent use.
2.2.3: Preparation and transformation of competent cells
2.2.3.1: Chemically competent cells
A single colony of the appropriate E. coli strain was used to inoculate 5 ml of LB
broth (containing the appropriate antibiotics if necessary) and was cultured at 37°C (or
30°C in the case of DH5α/BT340).  The next day, 500 μl of the overnight culture was
used to inoculate 50 ml of LB broth, which was incubated at the appropriate temperature
with shaking until OD600 ~ 0.4.  The culture was then transferred to a 50 ml falcon tube
and pelleted by centrifugation at 1,000 х g for 10 minutes at 4 °C.  The supernatant was
discarded and 5 ml of ice cold transformation and storage buffer [LB broth (pH 6.1), 10%
PEG v/v, 5% DMSO w/v, 20 mM Mg2+ (10 mM MgCl2 + 10 mM MgSO4)] was used to
re-suspend the pellet.  The cell suspension (100 μl) was rapidly aliquoted into pre-chilled
1.5 ml microfuge tubes and each tube was flash frozen in a liquid nitrogen bath before
being stored at -80°C for subsequent use. Before DNA transformation, competent cells
were thawed on ice for 30 minutes.  The DNA to be transformed (10 μl ligation reactions
or 5 ng pure plasmid/cosmid DNA) was added to 50 μl of thawed competent cells and
incubated on ice for 30 minutes.  Following incubation, the mixture was heat-shocked at
42°C for 30 seconds before being placed immediately on ice for 3-5 minutes.  The cells
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were then transferred to a 1.5 ml microfuge tube containing 950 μl of SOC (2% w/v
tryptone, 0.5% w/v yeast extract, 0.05% w/v NaCl, 0.0186% w/v KCl in dH2O with 10
mM MgCl2 and 20 mM of glucose added after autoclaving) and incubated at 37°C for 1
hour with shaking. After incubation, the cells were pelleted via centrifugation at 10,000
rpm for 2 minutes and 900 μl of the resulting supernatant was removed and discarded.
The pellet was re-suspended in the remaining 100 μl of supernatant and the entire volume
was plated onto a single LB plate containing the appropriate antibiotics.  Transformation
plates were incubated at the appropriate temperature overnight and successful
transformants were identified based on the growth of bacterial colonies on the following
day.  In the case of transforming ligations involving the vector pGEMT-Easy, (A1360,
Promega, Canada) blue/white screening was employed and white colonies were selected
for further analysis.
2.2.3.2: Electrocompetent cells
A single colony of E. coli BW25113/pIJ790 was used to inoculate 10 ml of LB
broth containing chloramphenicol before the culture was incubated overnight at 30°C
with shaking.  Afterwards, 100 μl of overnight culture was sub-cultured into 10 ml of
Super Optimal Broth (SOB) (2% w/v tryptone, 0.5% w/v yeast extract, 0.05% w/v NaCl,
0.0186% w/v KCl in dH2O) containing 20 mM MgSO4 and chloramphenicol (25 μg/ml).
This culture was incubated at 30°C with shaking until an OD600 of 0.4 was reached.  Cells
were pelleted by centrifugation at 4000 rpm for 5 minutes at 4°C.  The supernatant was
discarded and the pellet was re-suspended in 10 ml of ice cold, sterile 10% glycerol.  The
pellet was washed two more times with 5 ml ice cold 10% glycerol in this manner and
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finally the supernatant was discarded and the pellet was re-suspended in the remaining
~100 μl of 10% glycerol.  50 μl of the electrocompetent cell suspension was added to an
ice cold 0.2 cm electroporation cuvette and mixed with 100 ng of cosmid DNA.
Electroporation was carried out using a BioRad GenePulser Xcell™ (165-2662, Canada)
set to: 200 Ω, 25 μF and 2.5 kV. The time constant of successful transformations was
usually in the range of 5.0-5.2 ms.  Immediately after electroporation, 1 ml of ice cold LB
was added to the cells, which were then gently transferred to a fresh microfuge tube and
incubated at 30°C for 1 hour with shaking.   Afterwards, the cells were pelleted by
centrifugation at 4000 rpm for 5 minutes at and 900 μl of supernatant was drawn off and
discarded.  The cells were re-suspended in the remaining ~100 μl of supernatant before
being spread onto two LB agar plates supplemented with the appropriate antibiotics.
These plates were incubated overnight at 28°C and resulting antibiotic resistant colonies
were used to inoculate 5 ml LB broth supplemented with ampicillin (100 μg/ml),
kanamycin (50 μg/ml) and chloramphenicol (25 μg/ml).  These cultures were incubated
overnight at 30°C with 200 rpm shaking and glycerol stocks were prepared.
2.3: General Streptomyces procedures
2.3.1: Maintenance and stock preparation
All cultures of S. clavuligerus were grown at 28°C, with liquid cultures being
incubated with agitation at 200 rpm in 125 ml flasks with springs (unless indicated
otherwise). Strains of S. clavuligerus were maintained on either international ISP-4
medium (M359, HiMedia, India) or on MYM plates (0.4% w/v maltose, 0.4% w/v yeast
extract, 1% w/v malt extract and 1.8% w/v agar) and liquid cultures were grown in TSB
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(236950, BD Biosciences, USA) supplemented with 2% w/v starch (TSBS) (RM3029,
HiMedia, India). S. flavogriseus was cultured and maintained in TSB using the same
incubation conditions mentioned above. S. viridis was grown in liquid cultures of
Nutrient Broth (2340000, BD Difco, USA) at 45°C with agitation at 200 rpm in 125 ml
flask (with no spring).  Glycerol stocks were prepared by scraping growth (spores or
mycelia) from agar plates into a 1.5 ml microfuge tube containing 500 μl of 20% sterile
glycerol, before being stored at -80°C.  When required, antibiotics were included as listed
in Table 2.1.  All exconjugants were allowed to recover on AS-1 medium (0.01% w/v
yeast extract, 0.02% w/v L-alanine, 0.02% L-arginine, 0.05% w/v L-asparagine, 0.5%
soluble starch, 0.25% w/v NaCl, 1.0% w/v Na2SO4, 2.0% w/v agar, pH to 7.5 and 1% v/v
sterile 1 M MgCl2 added post- autoclaving).  For bioassays and HPLC analysis, strains
were grown in SA broth [1% w/v soluble starch; 0.2% w/v L-asparagine; 2.1% w/v
MOPS buffer; 0.06% w/v MgSO4; 0.44% w/v K2HPO4 in H2O; pH 6.8 and 1 ml of sterile
trace elements solution (0.10% w/v of each FeSO4, MnCl2, ZnSO4 and 0.13% w/v CaCl2)
per L of media (added after autoclaving].
2.3.2: Chromosomal DNA preparation
Chromosomal DNA was extracted from all S. clavuligerus, S. flavogriseus and S.
viridis cultures using the QIAamp DNA Mini Kit (QIAGEN Inc., Canada) using a
modified protocol.  From 25 ml of TSBS cultures, 1.5 ml was drawn and added to a
microfuge tube before the mycelia were harvested by centrifugation.  Subsequently, 200
μl of both ATL and AL buffer were added.  Approximately 600 μl of this cell suspension
was added to a 2 ml sterile screw cap tube containing sterile, acid-washed beads (BAWZ
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400-250-35, OPS Diagnostics, USA).  The samples were homogenized using a SpeedMill
PLUS Bead Homogenizer (845-00008-2, Analytik Jena AG, Germany) under the pre-
programmed “Bacteria” protocol (2 х 3 minute on and 3 minute off cycles).  Afterwards,
samples were centrifuged at 10,000 rpm for 1 minute, and the supernatants were
transferred to fresh 1.5 ml microfuge tubes containing 200 μl of 95% ethanol. After
vortexing briefly, the tubes were centrifuged again and the supernatants were transferred
to spin columns and centrifuged at 8,000 rpm for 1 minute.  Filtrates were discarded and
500 μl of AW2 Buffer was added to each column before centrifugation at 14,000 rpm for
3 minutes.  The filtrates were again discarded and tubes were centrifuged as above for an
additional minute to remove residual buffer and ethanol.  Columns were placed into
clean, sterile 1.5 ml microfuge tubes and 100 μl of dH2O was added to each column.
Columns were incubated at room temperature for 5 minutes before the DNA was eluted
via centrifugation at 8000 rpm for 1 minute and was stored at -20°C for subsequent use.
2.3.3: Chemical denaturation of S. flavogriseus chromosomal DNA for use in PCR
Genomic DNA (9 μl) prepared via the above method was mixed with 2 μl of 1 M
NaOH before incubating at 37°C for 10 minutes.  Afterwards, 2 μl of 1 M HCl was added
to the genomic DNA solution, which was then mixed immediately and placed on ice.
After the solution had cooled, 1 μg of genomic DNA from the sample was used for PCRs
amplification (refer to section 2.4.1.2 for PCR instructions).
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2.3.4: Standardization of cell growth for bioassays and HPLC
Cultures of different S. clavuligerus strains were started by dispensing a 1% v/v
mycelial inoculum into 25 ml of TSBS containing antibiotics as necessary and then
incubating for 36 hours.  Mycelia were then harvested by centrifugation at 3,500 rpm for
7 minutes before being washed twice with 10.3% w/v sucrose.  The pellet was re-
suspended in 2 ml of 20% glycerol and the OD595 of the suspensions were measured,
which were determined following a protocol modified from Brana et al. (1985).  Mycelial
suspension (500 μl) was mixed with 500 μl of 0.62 M HCl before being sonicated in a
water bath (Ultrasonic cleaner, ME 4.6, Mettler Electronics corp., USA) at room
temperature for 30 seconds.  Samples were then diluted 1/100 with 0.25 M HCl and the
OD595 was recorded for each sample.  According to the protocol, one unit of OD595 is
equivalent to 0.59 mg/ml dry cell weight when the final readings are below 0.6. Final
standardized stocks were made by diluting all samples with 20% glycerol to an OD595 of
25.  These diluted suspensions, were aliquoted into a microfuge tubes and stored as
mycelial stocks at -80°C.
2.3.5: Liquid cultures for bioassays and HPLC analysis
Cultures of each S. clavuligerus strain were started using a 1% v/v inoculum from
the standardized mycelial stocks (see section 2.3.4) in 10 ml of TSBS plus antibiotics (as
necessary) and incubated for 48 hours with shaking in 50 ml flasks without springs. SA
medium (25 ml) was inoculated with 200 μl of the above starter cultures in 125 ml flasks
without springs, and the flasks were incubated for 120 hours with shaking.  Culture
supernatants were sampled aseptically every 24 hours starting at 48 hours, with 1 ml
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being removed and transferred to clean sterile microfuge tubes.  Samples were stored at -
80°C for subsequent use in bioassays and HPLC analysis.
2.3.6: Liquid cultures for protein extraction
TSBS medium (10 ml) supplemented with hygromycin (200 μg/ml) was
inoculated with S. clavuligerus strains harbouring the FLAG tag expression plasmid for
blm, blip or ccaR (Table 2.2), and were incubated for 24 hours at 28°C with shaking.
Three ml from each starter culture was sub-cultured into 100 ml SA broth in 500 ml
flasks without springs.  These cultures were incubated at 28°C with shaking for 48 hours
before being used immediately for protein extraction or were frozen at -80C for further
analysis (as described later).
2.3.7: Mycelial conjugations
Cultures of either S. clavuligerus ∆blm::apraR or ∆blm-INF were started in 50 ml
of 2% TSBS containing appropriate antibiotics and were incubated for 36-40 hours at
28°C with shaking.  Subsequently, the cultures were centrifuged at 3,500 rpm for 7
minutes and washed twice in 25 ml of 2х YT medium (1.6% w/v tryptone, 1% w/v yeast
extract, 0.5% w/v NaCl, in H2O, pH 7.0) before being re-suspended in 5 ml of 2х YT
media.  The mycelial suspension was then homogenized using a Duall tissue grinder with
glass pestle (KT885450-0023, VWR International, Canada).  A 50 ml culture of the donor
E. coli strain ET12567/pUZ8002 containing the plasmid/cosmid to be mobilized was
grown in LB supplemented with the appropriate antibiotics (Table 2.2) to an OD600 of
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0.3-0.5.  Cells were centrifuged at 3,500 rpm and washed twice with LB before being re-
suspended in 1 ml of LB.  The homogenized mycelial were centrifuged as above and re-
suspended in 1 ml of 2х YT media.  Mycelial suspension (500 μl) was transferred to a
sterile 1.5 ml microfuge tube and heat-shocked at 40°C for 5 minutes with 300 rpm
shaking in an Eppendorf thermomixer (22331, Germany).  Immediately after heat-shock,
500 μl of the E. coli suspension was added to the mycelial suspension and mixed by
vortexing.  The entire 1 ml suspension was spread evenly onto AS-1 agar plates and after
24 hours of incubation at 28°C, the plates were overlaid with nalidixic acid (40 μg/ml,
final concentration) and an antibiotic for plasmid/cosmid transfer selection, before being
incubated for a further 1-2 weeks.  When adequate growth was obtained, colonies were
picked and homogenized with a sterile pipette tip in a 1.5 ml microfuge tube containing
20 μl of sterile H2O.  This suspension was plated onto ISP-4 media containing nalidixic
acid (40 μg/ml) and the previously used selection antibiotic before being incubated at
28°C for 2 weeks.  After incubation, growth was collected and scraped into 500 μl of 20%
glycerol.  These stocks were vortexed and stored at -80°C for subsequent use.
2.3.8: Spore conjugations
Spore conjugations were only performed using the wt S. clavuligerus strain.  A
culture of the donor E. coli ET12567/pUZ8002 containing the plasmid/cosmid to be
transferred (Table 2.2) was grown and processed as described above. S. clavuligerus wt
spores (100 μl) were washed in 1 ml of 2х YT broth followed by suspension in a 50°C
water bath for 10 minutes.  Spores were allowed to cool before mixing 500 μl of washed
E. coli cells and 500 μl of heat shocked spores in a microfuge tube.  The contents were
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pelleted by centrifugation at 10,000 rpm for 1 minute.  The supernatant was discarded and
the pellet was gently re-suspended in residual broth.  The entire suspension was spread
onto a freshly made AS-1 agar plates and incubated at 28°C for 24 hours.  The following
recovery and selection process was the same as described in the above mycelial
conjugation protocol (see section 2.3.7).
2.3.9: Determination of dry cell weights
After 96 hours of incubation during fermentation studies using SA medium, 1 ml
of each culture (section 2.3.5) was removed and transferred to microfuge tubes.  Mycelial
pellets were obtained by centrifugation at 10,000 rpm and the majority of the supernatant
was drawn off with special consideration to not disturb or remove any of the pellets.  The
pellets were re-suspended in the remaining supernatant and each one was transferred to
one, pre-weighed, small aluminum weigh boat (12577-062, VWR International, Canada).
H2O (100 μl) was added to each microfuge tube to resuspend any remaining mycelia and
to ensure that all growth was removed and transferred to each weigh boat.  Afterwards,
the pellets in the weigh boats were dried for 72 hours at 100°C and were then left to cool
to room temperature before weights were recorded.  Dry cell weights were determined by
subtracting the weight of the weigh boat from that of the weigh boat and dried pellet.
2.4: General DNA procedures
2.4.1: PCR and agarose gel-electrophoresis conditions
The primers listed in Table 2.3 were used for performing the various PCR
reactions and DNA sequencing analysis conducted during the described study.
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Table 2.3: Oligonucleotide primers used in this study with their primer pair, Tm and purpose
Primer Name Sequence Restriction
enzyme site Used with Tm (°C) Purpose
blm-RD-F 5’-ATG ATG AAG AAA GCT GAT TCC GTC CCG ACCCCG GCT GAG ATT CCG GGG ATC CGT CGA CC-3’ None blm-RD-R Multi Introduction of apra-oriT cassette in
place of blm in genetic reading frameblm-RD-R 5’-TCA TCG CCG GGC GGC TTC TCC GGC GCT CGCGCG GTC GTC TGT AGG CTG GAG CTG CTT C-3’ None blm-RD-F Multi
blm-CONF-F 5'- CCG ACA AGG AGC GAT GAT GA-3' None blm-CONF-R
57 (Taq)
68 (Phus) Confirm DNA in position of blm,
could be blm, apra-oriT cassette or
scarblm-CONF-R 5'- GGA TCA CAC CGA AGC CCA GT-3' None blm-CONF-F
57 (Taq)
68 (Phus)
pIJ773-R 5'-TCG CTA TAA TGA CCC CGA AG-3' None blm-CONF-R 51 (Taq)
Shows direction of apra-oriT
cassette in S. clavuligerus
Δblm::apraR mutants
pWE15-amp-RD-F 5'-TGA TAA ATG CTT CAA TAA TAT TGA AAA AGGAAG AGT ATG ATT CCG GGG ATC CGT CGA CC-3' None
pWE15-
amp-RD-R Multi Introduction of hyg-oriT cassette into
ampR in 12B8 cosmid (Redirect)pWE15-amp-RD-R 5'-AAT CTA AAG TAT ATA TGA GTA AAC TTG GTCTGA CAG TTA TGT AGG CTG GAG CTG CTT C-3' None
pWE15-
amp-RD-F Multi
pIJ799-F 5'-CCCTGATAATGCTTCAATAATATTGAAAA-3' None pIJ799-R 49 (Taq) Confirms DNA in position of ampR,
could be ampR or hyg-oriT cassette,
in 12B8 cosmidpIJ799-R 5'-AAT CAA TCT AAA GTA TAT ATG AGT AAA CTTGGT C-3' None pIJ799-F 49 (Taq)
HygR-F 5'-CGC ATA GAC GTC GGT GAA GT-3' None HygR-R 56 (Taq) Confirms presence or absence of
hygR
HygR-R 5'-TAC CTG GTG ATG AGC CGG AT-3' None HygR-F 56 (Taq) Confirms presence or absence ofhygR
blip-FLAG-F 5'-ATA CAT ATG AGG ACA GTG GGG ATC G-3' NdeI blip-FLAG-R 3-step Amplification of blip from S.
clavuligerus with FLAG tag attachedblip-FLAG-R 5'-ATG GAT CCT CAC TTG TCG TCG TCG TCC TTGTAG TCT ACA AGG TCC CAC TGC CGC TTG-3' BamHI
blip-FLAG-
F 3-step
ccaR-FLAG-F 5'-TAC ATA TGA ACA CCT GGA ATG ATG TGA C-3' NdeI ccaR-FLAG-R 3-step Amplification of ccaR from S.
clavuligerus with FLAG tag attached
ccaR-FLAG-R 5'-ATG GAT CCT CAC TTG TCG TCG TCG TCC TTGTAG TCG GCC GGG GTA CCG ACC-3' BamHI
ccaR-
FLAG-F 3-step
blm-FLAG-F 5'- TAC ATA TGA TGA AGA AAG CTG ATT CCG TC-3' NdeI blm-FLAG-R 3-step Amplification of blm from S.
clavuligerus with FLAG tag attachedblm-FLAG-R 5'- ATG GAT CCT CAC TTG TCG TCG TCG TCC TTGTAG TCT CGC CGG GCG GCT TC-3' BamHI
blm-FLAG-
F 3-step
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blm-SC-F 5’-ATA CAT ATG ATG AAG AAA GCT GAT TCC G-3’ NdeI blm-SC-R 67 (Phus) Amplification of blm from S.
clavuligerusblm-SC-R 5’-ATA GGA TCCTCA TCG CCG GGC GGC TTC-3’ BamHI blm-SC-F 67 (Phus)
blm-SF-F 5’-TAC ATA TGA TCG ATC TAC CCG GTT CCG-3’ NdeI blm-SF-R 72 (Phus) Amplification of blm from S.
flavogriseusblm-SF-R 5’-ATA AGC TTC ACCGGG AGG TGC CGG-3’ HindIII blm-SF-F 72 (Phus)
blm-SV-F 5’-TAC ATA TGT TGA CCA CTA CCG AGA C-3’ NdeI blm-SV-R 66 (Phus)
Amplification of blm from S. viridis
blm-SV-R 5’-ATA AGC TTC ACG GCA GCA ACG AGT G-3’ HindIII blm-SV-F 66 (Phus)
Multi- Redirect PCR method outlined by Gust et al. 2003 was used. See section 2.5.1; (Taq)- Tm used in conjugation with Taq DNA polymerase; (Phus)- Tm used in
conjunction with Phusion DNA polymerase; 3-step- Phusion 3-step PCR method was used. See section 2.4.1.1
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2.4.1.1: PCR to confirm the deletion of the blm gene in cosmid and genomic DNA
Several DNA oligonucleotide primer pairs (Table 2.3) were used to confirm the
replacement of the blm gene with either the apramycin cassette or the 81 bp scar DNA
sequence.  These PCR reactions were carried using either purified cosmid DNA or S.
clavuligerus genomic DNA as template, depending on the stage of the Redirect PCR
targeting process (Gust et al. 2003).  Either 1 μg of S. clavuligerus genomic DNA or 200
ng of cosmid DNA was used as template along with Fisher BioReagents® Taq DNA
polymerase (FB-6000-15, Fisher Scientific, Canada,) with Buffer A, 3% v/v DMSO and 1
M betaine, as per manufacturer’s instructions.  The thermocycling conditions were as
follows: initial denaturation at 95°C for 3 minutes with 35 cycles of denaturation at 95°C
for 30 seconds, variable annealing at temperatures for 30 seconds and extension at 72°C
for 2 minutes, followed by a final extension step at 72°C for 5 minutes.  Annealing
temperatures (X°C) are variable and DNA oligonucleotide primer dependent as indicated
in Table 2.3.
2.4.1.2: PCR of blm from S. clavuligerus, S. viridis and S. flavogriseus
The blm gene from each species was amplified using oligonucleotide primers
described in Table 2.3 along with 1 μg of purified genomic DNA as template from each
organism (S. flavogriseus genomic DNA was chemically denatured prior to use in PCR;
see section 2.3.3) and Phusion High-Fidelity DNA Polymerase (F-5302, Fisher Scientific,
Canada) with high GC buffer, 3% v/v DMSO and 1 M betaine, as per manufacturer’s
instructions.  The following thermocycling conditions were used: initial denaturation at
98°C for 1 minute and then 30 cycles of denaturation at 98°C for 15 seconds, annealing at
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variable temperatures for 15 seconds and extension at 72°C for 1.5 minutes, followed by a
final extension at 72°C for 5 minutes.  Annealing temperature (X°C) is variable and
depends on the oligonucleotide primer pair used as described in Table 2.3.
2.4.1.3: PCR and FLAG tagging of blm, ccaR and blip for protein localization studies
All three S. clavuligerus genes were amplified using oligonucleotide primers
described in Table 2.3 along with 1 μg of S. clavuligerus genomic DNA as the template,
Phusion High-Fidelity DNA Polymerase with High GC buffer, 3% v/v DMSO and 1 M
betaine, as per manufacturer’s instructions.  The following three step thermocycling
conditions were used for the reactions: initial denaturation at 98°C for 30 seconds; then
10 cycles of denaturation at 98°C for 10 seconds, annealing at 60°C for 30 seconds and
extension at 72°C for 1 minute; followed by 10 cycles of denaturation at 98°C for 10
seconds, annealing at 65°C for 30 seconds and extension at 72°C for 1 minute; and finally
15 cycles of denaturation at 98°C for 10 seconds, annealing at 72°C for 30 seconds and
extension at 72°C for 30 seconds.  A final extension at 72°C for 3 minutes was conducted
at the end.
2.4.1.4: Agarose gel-electrophoresis
All reactions were loaded on to either a 0.8% w/v (for fragments >1 kb) or 1.5%
w/v (for fragments ≤1 kb) agarose gels using 6х loading dye (30% v/v glycerol, 0.25%
w/v bromophenol blue, 0.25% xylene cyanol). The GeneRuler™ 1 kb ladder (SM0321,
Thermo Scientific, USA) or the GeneRuler™ 100 bp Plus ladder (SM0321, Thermo
Scientific, USA) were used as molecular weight markers for the analysis.  Electrophoresis
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was performed in 1х TBE buffer (89 mM Tris base, 89 mM Boric acid, 2 mM EDTA, pH
8) at a constant voltage between 95-120 V, depending on the gel size.  Before imaging,
gels were stained in 0.5 μg/ml ethidium bromide solution (L07482, Alfa Aesar, USA) for
30 minutes and then de-stained in H2O for 15 minutes.  Images of the gels were then
obtained using a ChemiImagerTM Ready imager (DE500, Canberra Packard, Canada).
2.4.2: Cloning with pGEM®-T Easy and pHM11a
2.4.2.1: pGEM®-T Easy
All genes later expressed in S. clavuligerus (blmSC, blm-like genes and FLAG-
tagged genes) were originally cloned into the pGEM®-T Easy vector (A1360, Promega,
USA).  Ligation of PCR products with the pGEM®-T Easy vector was carried out
according to the manufacturer’s instructions.  Polyadenylation of PCR products was
achieved through the use of Fisher BioReagents® Taq DNA polymerase (recombinant,
FB-6000-15, Fisher Scientific Canada) in 10 μl reactions with the following components:
1х Taq Buffer A, 0.2 mM dNTPs and up to 8.7 μl of PCR product.  The reactions were
incubated at 72°C for 10 minutes before immediately being added to ligation reactions
containing the pGEM®-T Easy vector.  The reactions were left at 4°C overnight before
transformation into E. coli NEB5α (as discussed in section 2.2.3.1).  After blue/white
screening, plasmid DNA from each strain was isolated using the modified alkaline lysis
method.  Restriction enzyme digestion using EcoRI and subsequent gel electrophoresis
was performed to screen plasmids for the presence of positive clones.
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2.4.2.2: pHM11a
Each positive PGEM®-T Easy clone (1 μg) was digested to excise the previously
cloned insert from above (blmSC, blm-like genes and flag-tagged genes) with restriction
enzymes corresponding to the sites engineered into the respective primers (Table 2.3).
SspI was also included in each digestion to cut the pGEM®-T Easy backbone in order to
promote ligation of DNA fragments containing genes of interest into pHM11a (Motamedi
et al. 1995) instead.  After overnight digestion, the DNA was added to 0.5 ng of pHM11a
previously digested with the same enzymes in addition to FastAP thermosensitive
alkaline phosphatase (EF0654, Thermo Fisher Scientific Inc., Canada). Before combining
the two samples, all enzymes were heat inactivated by incubating at 80C for 20 minutes.
The combined DNA was co-precipitated by adding 1/10 volume of 3 M sodium acetate
and 2 volumes of ice cold absolute ethanol and contents were vortexed.  The samples
were incubated overnight at -20°C, after which they were centrifuged at 14,000 rpm at
4°C for 15 minutes in an Eppendorf 5417R centrifuge with an F45-30-11 rotor.  The
supernatant was discarded and the pellet was dried by aspiration.  Subsequently, 300 μl of
ice cold 70% ethanol was added and the tubes were centrifuged again (as above) for 5
minutes.  The supernatant was discarded and the pellet was dried again in laminar flow
hood with the caps open until they became colourless.  The DNA pellets were re-
suspended in 35 μl of sterile H2O for use in ligations.
Ligations with the pHM11a vector were carried out in 10 μl reactions using 1 μl of
T4 DNA Ligase (M0202S, New England Biolabs, USA), 1х NEB ligation buffer and 8 μl
of ethanol-precipitated DNA from above.  All ligation reactions were incubated overnight
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at 18-20°C before being transformed into E. coli NEB5α (as discussed in section 2.2.3.1).
The DNA sequence of each insert was determined using a combination of primers (Table
2.3) at The Centre for Applied Genomics (TCAG, University of Toronto, Canada) to
confirm the absence of mutations, before the plasmids were introduced into S.
clavuligerus Δblm-INF, Δblm::apraR and wt strains via mycelial or spore conjugation.
2.5: The creation of S. clavuligerus Δblm mutants
2.5.1: PCR targeting and preparation of the 12B8 Δblm-AP cosmid
Redirect PCR primers were designed to amplify the apramycin cassette from the
plasmid pIJ773 while adding DNA sequences from the upstream and downstream region
of blm to each end of the PCR product.  The apramycin resistance cassette was released
from pIJ773 as a result of an EcoRI and HindIII digest. The cassette was then gel
purified as described above in section 2.1.  The purified apramycin cassette was used as
the template DNA in a PCR reaction using the blm-RD primers (Table 2.3) along with
Phusion High-Fidelity DNA Polymerase with high GC Buffer, 3% v/v DMSO and 1 M
betaine, as per manufacturer’s instructions.  The following two step thermocycling
conditions were used: initial denaturation at 98°C for 1 minute; then 10 cycles of
denaturation at 98°C for 5 seconds, annealing at 50°C for 15 seconds and extension at
72°C for 2 minutes; followed by 15 cycles of denaturation 98°C 5 seconds, annealing at
55°C for 15 seconds and extension at 72°C for 2 minutes; and finally a final extension at
72°C for 5 minutes.  The resulting PCR product contained the apramycin cassette flanked
by sequences complementary to DNA directly upstream and downstream of blm from the
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S. clavuligerus chromosome.  The size of the PCR product was confirmed by gel
electrophoresis followed by gel purification.
SOB broth (50 ml) containing the appropriate antibiotics was inoculated with 1 ml
of overnight E. coli BW25113 containing pIJ790 and cosmid 12B8 (12B8 was previously
electroporated into this strain via the method outline in section 2.2.3.2). Five hundred
microliters of 1 M L-arabinose stock solution (10 mM final) was added to induce the red
genes of pIJ790 before the culture was incubated at 30°C with 200 rpm shaking until the
OD600 approached ~0.3 (~ 3 hours).  An additional 500 μl of 1 M L-arabinose solution (10
mM final) was then added and the culture was incubated for another 30-40 minutes.
Cultures were transferred into sterile 50 ml falcon tubes and cells were recovered by
centrifugation at 4000 rpm for 5 minutes at 4°C.  The supernatant was discarded and the
pellet was re-suspended in 10 ml of ice cold 10% glycerol before centrifuging as above.
The process was repeated after which the supernatant was discarded and the pellet was re-
suspended in the ~100 μl residual 10% glycerol. Fifty microliters of the cell suspension
was mixed with ~500-800 ng of purified apramycin PCR product (from above) before
electroporation was carried out in an ice cold 0.2 cm electroporation cuvette using a
BioRad GenePulser set to: 200 Ω,25 μF and 2,5 kV.  Ice cold LB (1 ml) was immediately
added and cells were incubated at 37°C with 200 rpm shaking for 1 hour.  Afterwards, the
cells were pelleted by centrifugation at 4000 rpm for 5 minutes at 4°C and 900 μl of the
resulting supernatant was discarded.  The cells were re-suspended in the remaining ~100
μl of supernatant and the cell mixture was spread onto two low sodium LB (1% w/v
tryptone, 0.5% w/v yeast extract, 0.25% w/v sodium chloride) agar plates supplemented
with kanamycin (50 μg/ml) and apramycin (100 μg/ml).  These cultures were incubated
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for 16-24 hours at 37°C to promote the loss of pIJ790.  Antibiotic resistant colonies were
used to inoculate 5 ml of LB broth supplemented with kanamycin (50 μg/ml) and
apramycin (100 μg/ml).  These cultures were incubated overnight at 37°C with 200 rpm
shaking and glycerol stocks were made the following day.
The resulting 12B8 ∆blm-AP cosmid was verified via PCR amplification of the
blm region and was transformed into E. coli ET12567/pUZ8002 and plated onto LB agar
supplemented with apramycin (50 μg/ml), chloramphenicol (25 μg/ml) and kanamycin
(25 μg/ml).  Isolated colonies were picked and cultured in 5 ml of LB broth supplemented
with antibiotics (as above) before being incubated overnight at 37°C with 200 rpm
shaking for preparing glycerol stocks.
2.5.2: Preparation of the S. clavuligerus blm::apraR mutant
The engineered cosmid from above (12B8 ∆blm-AP), was conjugated from E. coli
ET12567/pUZ8002 into S. clavuligerus wt via spore conjugation (section 2.3.8).  After
the initial 30 hours incubation, the conjugation plates were overlaid with nalidixic acid
(40 μg/ml) and apramycin (25 μg/ml) before being incubated for a further 2 weeks.
Thereafter, colonies were picked and homogenized with a sterile pipette tip in a 1.5 ml
microfuge tube containing 20 μl of sterile H2O.  This suspension was plated onto ISP-4
medium containing nalidixic acid and apramycin before being incubated at 28°C for 2
weeks.  After incubation, growth was collected in a microfuge tube and 500 μl of 20%
glycerol was added.  These stocks were vortexed and placed at -80°C for subsequent use.
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To verify the blm replacement, glycerol stocks of suspected S. clavuligerus
blm::apraR colonies were thawed on ice and serially diluted to 10-6 using sterile H2O.
Each dilution (100 μl) was spread onto MYM agar supplemented with nalidixic acid and
apramycin and incubated at 28°C.  After 1 week, isolated colonies from each strain were
crushed with a pipette tip in 30 μl sterile H2O. Twenty microliters of this suspension was
plated onto ISP-4 media containing apramycin and the remaining 10 μl was plated onto
MYM agar containing kanamycin.  These plates were left to incubate for 2 weeks before
colony growth on each plate was compared.  Growth from plates containing mutant
strains sensitive to kanamycin and resistant to apramycin were scraped and placed in a 1.5
ml tube containing 500 μl of 20% glycerol before being stored at -80°C for subsequent
use. The S. clavuligerus blm::apraR mutants were genetically confirmed via PCR of the
blm region (section 2.4.1.1) using genomic DNA (section 2.3.2) as the template DNA.
2.5.3: FLP-mediated excision of the apramycin cassette from 12B8 ∆blm-AP
The 12B8 ∆blm-AP cosmid was transformed into chemically competent E. coli
DH5α/BT340 cells as outlined above (section 2.2.3).  All steps including incubation were
done at a temperature of 30°C or lower to maintain FLP synthesis and plasmid
replication.  The transformation mixture was plated onto LB agar supplemented with the
appropriate antibiotics (Table 2.2) before being incubated at 30°C for 48 hours.
Subsequent colonies were streaked onto LB agar plates without antibiotics and these
plates were incubated at 42°C overnight to promote FLP recombinase expression and loss
of the BT340 plasmid.  The following day, the antibiotic resistance profile of 10 colonies
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from the growth plates was tested against ampicillin and apramycin.  This was conducted
by dividing a single colony into 3 portions and spotting each third of a colony onto the
following media: a LB agar plate, LB agar containing ampicillin and LB containing
apramycin.  Afterwards, these plates were incubated at 37°C overnight.  Colonies that
were ampicillin resistant and apramycin sensitive were verified by PCR analysis (see
section 2.4.1.1) before glycerol stocks were made and stored at -80°C.  These colonies
contained the engineered cosmid 12B8 ∆blm::scar.
2.5.4: Replacement of the ampicillin resistance gene with the hygR cassette
The hygromycin resistance cassette was released from pIJ10700 as a result of a
SmaI and HindIII digestion before being gel purified using the EZ-10 Spin Column DNA
Gel Extraction Kit (section 2.1).  The purified hygromycin cassette was used as template
DNA in a PCR reaction using the pWE15-amp-RD primers (Table 2.3), Fisher
BioReagents® Taq DNA polymerase with Buffer A, 3% v/v DMSO and 1 M betaine, as
per manufacturer’s instructions.  The following two step thermocycling conditions were
used for the reactions: initial denaturation at 95°C for 3 minutes; then 15 cycles of
denaturation 95°C for 30 seconds, annealing at 50°C for 30 seconds, and extension 72°C
for 2 minutes; followed by 30 cycles of denaturation 95°C for 30 seconds, annealing at
55°C for 30 seconds, and extension 72°C for 2 minutes; and finally a final extension at
72°C for 5 minutes.  The resulting PCR product contained the hygromycin gene flanked
by sequences complementary to the beginning and end of the ampicillin resistance gene
located on the 12B8 ∆blm::scar cosmid (pWE15 backbone, Wahl et al. 1987).  The PCR
product size was confirmed with gel electrophoresis before gel purification.  PCR
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targeting was carried out as above (section 2.5.1) except for the following changes.  The
SOB broth contained ampicillin (100 μg/ml), kanamycin (50 μg/ml) and chloramphenicol
(25 μg/ml) with 1 ml of overnight BW25113/pIJ790/12B8 ∆blm::scar culture (created via
electroporation of 12B8 ∆blm::scar via the method outlined above in section 2.2.3.2).
Before electroporation, 50 μl of cells were mixed with ~500-800 ng of purified
hygromycin PCR product (from above).  Afterwards the cells were spread onto two low
sodium LB agar plates supplemented with kanamycin and hygromycin.  Inoculated plates
were incubated for 24 hours at 37°C to promote the loss of pIJ790.  The resulting
antibiotic resistant colonies were used to inoculate 5 ml low sodium LB supplemented
with kanamycin and hygromycin.  These cultures were incubated overnight at 37°C with
200 rpm shaking and glycerol stocks were made.  The resulting 12B8 ∆blm::scar
Δamp::hyg-oriT cosmid was verified via PCR amplification of both the scar sequence and
a 400 bp portion of the hygromycin gene.  As well, the antibiotic resistance profile was
determined for individual colonies of each strain by streaking half of a colony onto LB
agar containing ampicillin and streaking the remaining half of the colony onto LB agar
containing hygromycin.  After a 24 hour incubation period, colonies that were ampicillin
sensitive and hygromycin resistant were used to start new liquid cultures in order to make
glycerol stocks. Upon cosmid confirmation, 12B8::scar Δamp::hyg-oriT was
transformed into E. coli ET12567/pUZ8002 and plated onto two low sodium LB agar
plates supplemented with the appropriate antibiotics (Table 2.2).  Isolated colonies were
selected and cultured in low sodium LB broth supplemented with the same antibiotics
before being incubated overnight at 37°C with 200 rpm shaking. Glycerol stocks were
made and stored.
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2.5.5: Preparation of the S. clavuligerus blm-INF mutant
The cosmid engineered above (12B8::scar Δamp::hyg-oriT), was conjugated from
E. coli ET12567/pUZ8002 into the S. clavuligerus Δblm::apraR mutants (section 2.5.2)
via mycelial conjugation (section 2.3.7).  After the initial 24 hour incubation, the
conjugation plates were overlaid with nalidixic acid and kanamycin before being
incubated for a further 1.5 weeks.  Thereafter, colonies were picked and homogenized
with a sterile pipette tip in a 1.5 ml microfuge tube containing 20 μl of sterile H2O.  This
suspension was plated onto ISP-4 media containing nalidixic acid and incubated at 28°C.
After 2 weeks, growth was collected glycerol stocks were made and stored for further
analysis.
To verify gene replacement, glycerol stocks of suspected Δblm-INF colonies were
thawed on ice and serially diluted to 10-6 dilution using sterile H2O.  Each dilution (100
μl) was spread onto ISP-4 medium and incubated at 28°C for 2 weeks.  Once large,
isolated colonies appeared, a replica plating tool (25395-380, VWR International,
Canada) and a sterile velveteen square was used to replica plate each ISP-4 dilution onto
the following MYM agar plates: one without antibiotics, one containing kanamycin, and
containing apramycin.  These plates were left to incubate for 2 weeks before colony
growth on each plate was compared.  Colonies sensitive to both kanamycin and
apramycin were picked and homogenized with a sterile pipette tip in a 1.5 ml tube
containing 100 μl of 20% glycerol.  Of this suspension, 50 μl was plated onto ISP-4
media and incubated at 28°C for 2 weeks.  After incubation, growth was collected and
glycerol stocks were made and stored for further analysis. The Δblm-INF mutants were
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genetically confirmed via PCR of the blm region (section 2.4.1.1) using genomic DNA
(section 2.3.2) from each as the template DNA.
2.6: Determination of antibiotic production
2.6.1: Bioassays for the detection of clavulanic acid
Bioassays were used to detect CA produced in culture supernatants (Mosher et al.
1999). TSB agar (TSBA; 200 ml) containing 1 ml of an overnight culture of Klebsiella
pneumoniae (grown in TSB) and penicillin G (6 μg/ml) was poured into an ethanol-
sterilized 22 х 22 cm plastic bioassay tray.  As a control, another sterile tray was set up
the same way, but without the addition of penicillin G to the medium.  Sterile filter paper
discs (10 mm, 1001-185, Whatman, UK) were aseptically placed on top of the agar in
each tray and 10 μl of S. clavuligerus culture supernatant was spotted onto the filter paper
discs.  The trays were incubated overnight at 37°C right side up and the zones of
inhibition were measured and recorded.  Bioassay plates were imaged using a UVP Gel
Doc-ITTS2 310 Imager under white light.
2.6.2: HPLC analysis for the detection of clavulanic acid
HPLC analysis of S. clavuligerus culture supernatants was performed to detect
and quantify CA production by different strains as described before (Foulstone and
Reading 1982, Paradkar and Jensen 1995) with some modifications. An Agilent
Technologies 1260 Infinity Quaternary LC system with a 100 х 8 mm BondcloneTM
10μm C18 148 Ǻ LC column (00D-2117-L0, Phenomenex Inc., USA) was used in the
analysis.  Supernatants in microfuge tubes were centrifuged at 12,000 rpm for 5 minutes
before 100 μl was taken and derivatized with imidazole (10284730, Fisher Scientific
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Canada) (25 μl of 20.6% w/v imidazole in water solution, pH 6.8 using concentrated HCl)
for 15 minutes in the dark at room temperature. Control samples were prepared in the
same way with 100 μl of supernatant mixed with 25 μl HPLC-grade H2O. All samples
were centrifuged at 12,000 rpm for another 5 minutes to remove particulate matter before
100 μl of each sample was transferred to flat bottom glass inserts (5181-3377, Aglient
Technologies Canada Inc.).  Each insert was placed inside a screw-cap glass vial (5181-
3377, Aglient Technologies Canada Inc.) and loaded into the LC system. Samples (25 μl)
were injected onto the column at a flow rate of 2 ml/min, and sample components were
separated using a run time of 15 minutes with an isocratic mobile phase of sodium
phosphate buffer (1 M Na2HPO4, 6% v/v CH3OH, pH to 3.2 with glacial acetic acid).
Absorbance at wavelengths corresponding to 311 nm, 317 nm and 320nm was monitored
using the diode array detector and the Agilent ChemStation for LC 3-D Systems
(G2170BA, revision: B.04.03, Agilent Technologies Canada Inc.) software was used to
analyze the resulting data.
2.7: Western analysis of flag tagged proteins
2.7.1: Cytoplasmic protein extraction
One hundred milliliters of S. clavuligerus cultures were transferred to 2 х 50 ml
tubes and centrifuged at 3,500 rpm for 7 minutes.  The supernatant and the mycelial pellet
were separated and frozen at -80°C if not used immediately. The pellet volume was made
up to 5 ml with lysis buffer (150 mM HEPES and 150 mM NaCl, pH 7.5) and vortexed
vigorously.  Afterwards, 3 ml of each mycelial suspension was transferred to 3 ml screw
cap cryovials (0566965, Fisher Scientific, Canada) and sonicated on ice using a QSonica
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sonicator (Q125-110, VWR International, Canada) with a 5/64 inch probe (FB4423,
Fisher Scientific, Canada).  The sonication program consisted of 12 cycles of 15 seconds
on and 15 seconds off for a total of 6 minutes.  Sonicated mycelia were aliquoted into 3 х
1 ml microfuge tubes and centrifuged at 10,000 rpm for 10 minutes before the
supernatants were carefully removed from the pellet and placed in fresh microfuge tubes.
Protein quantification was performed using the OmniPur Bradford Method Protein Assay
(2740-OP, EMD Millipore, Canada).  Previously, a standard curve using this kit was
prepared according to manufacturer’s instructions through the use of Bovine Serum
Albumin (BSA).  All protein supernatants were stored at -80°C when not in use.
2.7.2: Ammonium sulfate precipitation of proteins from culture supernatant
Approximately eighty-seven millilitres of culture supernatant (separated from the
above mycelial pellet in the first step; section 2.7.1) were transferred to 2 х 50 ml tubes
and centrifuged in a Thermo Scientific Sorvall RC 6+ centrifuge at 27,000 хg for 15
minutes.  The supernatant was carefully poured into a vacuum filtration apparatus
(87006-062, VWR International, Canada) and filtered through a 0.2 μm filter to remove
any residual mycelia.  Filtered supernatant was transferred into a 500 ml flask containing
a stir bar.  Over a period of 1 hour, 44.9 g of ammonium sulfate was added gradually with
constant stirring at 4°C to give 80% saturation.  The protein that precipitated from
solution was collected by high speed centrifugation as described above.  The supernatant
was discarded and the protein pellet was left to air dry in the inverted tubes.  After 10
minutes, the pellet was re-suspended in 500 μl of 1 M phosphate buffer (sodium
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phosphate, pH 7.0) and protein quantification was performed as mentioned above (section
2.7.1).  Protein samples were stored at -80°C for subsequent analysis.
2.7.3: SDS-PAGE and western blot analysis
To visualize proteins, 20 or 50 μg of each protein sample was placed in a
microfuge tube along with 1х protein loading dye (EC-887, National Diagnostics, USA),
2.5% v/v of DTT and sample buffer (either lysis buffer or phosphate buffer depending on
sample type) to make up the final volume to 20 μl.  Samples were boiled at 100°C for 5
minutes before immediately being put on ice.  A total of ~20 μl of each sample was
loaded onto an SDS 12% PAG (resolving gel: 12% w/v acrylamide/bis-acrylamide, 50%
w/v 1.5 M Tris-HCl- pH 8.8, 0.01% w/v each of SDS and ammonium persulfate (APS)
and 0.1% v/v TEMED; stacking gel: 3.2% w/v acrylamide/bis-acrylamide, 25% w/v 0.5
M Tris-HCl-pH 6.8, 0.01% w/v each of SDS and APS and 0.1% v/v TEMED).  Both the
Thermo Scientific PageRuler Plus Prestained Protein Ladder (26619) and the PiNK Plus
pre-stained protein ladder (PM005-0250) (5 μl each) were loaded and used as protein size
markers.  Electrophoresis was performed at room temperature and 150 V for 75 minutes
using a BioRad Mini-PROTEAN® Tetra System (165-8001, BioRad, Canada) with 1х
Tris-glycine electrophoresis buffer (50 mM Tris-HCl pH 8.3, 380 mM glycine and 0.1%
w/v SDS).  Gels were soaked in transfer buffer (19.2 mM Tris-HCl pH 8, 192 mM
glycine, 0.015% w/v SDS, 20% v/v methanol) for 10 minutes before the proteins were
transferred from the gel to a Millipore Immobilon®-P PVDF (polyvinylidene difluoride)
Membrane (IPFL00010, Canada) using the BioRad Trans-Blot® Cell (170-3930, Canada)
according to manufacturer’s instructions.  The transfer was performed at 100 V with 380
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mA for 1 hour at 4 °C.  The membrane was washed 3 х 5 minutes with HPLC-grade H2O
and 1 х 5 minutes with TBS-T buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, and 0.5%
v/v Tween-20).  The membrane was blocked overnight at 4°C in blocking buffer (TBS-T
with 10% w/v non-fat milk: Instant Skim Milk, Carnation). Anti-FLAG antibodies (PA1
984B, Thermo Scientific Pierce, USA) were diluted to 1:500 in blocking buffer and were
incubated on the membrane for 1 hour with gentle rocking.  TBS-T was used to perform
several washes of the membrane (2 quick washes, 2 х 5 minute washes and 1 х 15 minute
wash) before the secondary antibody (diluted to 1:400, SA1200, Thermo Scientific
Pierce, USA) was added and incubated on the membrane for 1 hour with gentle rocking.
The membrane was washed again (as above) before being developed with ECL Western
Blot Substrate (W1001, Promega, USA) and imaged with a GE ImageQuant LAS 4000
Digital Imaging System (28-9558-10, GE Healthcare).  Resulting images were analyzed
using the ImageQuant TL software (GE Healthcare).
2.7.4: Determining protein weights using a standard curve
A standard curve (Supplementary Figure 12) was created for each membrane to
accurately determine the weights of each protein in comparison to the protein weight
ladders.  The program ImageJ (Schneider et al. 2012) was used to analyze each
membrane.  First, a measurement was set in ImageJ by drawing a short line across a photo
of a 30 cm ruler taken with the digital imaging system set to the same settings used to
develop the membranes.  Thus, the line drawn was of known length and was used to set
the ImageJ scale.  Next, the distance travelled (in millimeters) by each band of both
ladders as well as the loading dye (dye front) was determined and recorded in Microsoft
59
Excel.  Subsequently, as laid out in Bio-Rad’s guide to Molecular Weight Determination
by SDS-PAGE (Tech Note 3133), the Rf value of each band was calculated using the
following equation: Rf = migration distance of the protein/migration - distance of the dye
front.  Once this was completed, a graph plotting the Rf values versus the log of the
known molecular weight of each band (log MW) was created.  Through the addition of a
trend line to the data, a straight line equation (y=mx + b) was obtained for each data set
(Supplementary Figure 12).  Since the accuracy of the calculated molecular weight
depends on the linearity of the relationship, the two largest proteins of each ladder were
removed from the graph.  This moved the r2 value closer to 1, which is an increase in
linearity.  Using these two equations, the molecular weights of the unknown proteins
were determined by entering the Rf values of each unknown protein into the respective
line equation and solving for “y”.
The expected weights of each protein were determined using the published
nucleotide sequence of each gene (blm: AY258009; ccaR: AH006362; blip: M34538) and
translating them to their amino acid sequences.  The molecular weight (1 kDa) of the
FLAG tag was added to the expected weight and this value (theoretical) with the
experimentally determined value was used to calculate percent error (% error) in the
equation % error = ( )( ) × 100.
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Chapter 3: Results
3.1: Preparation of the Δblm mutants
In order to create a blm in-frame mutant using the Redirect method, blm on the S.
clavuligerus chromosome must be replaced with an 81 bp scar sequence in the correct
reading frame. PCR primers (blm-RD-F and –R; Table 2.3) were designed so that the 5'
ends were homologous to the beginning and the end region of the blm gene.  The 3′ ends
of these primers were homologous to the apramycin resistance cassette from pIJ773.  The
resistance cassette in pIJ773 consists of the apramycin resistance gene (aac(3)IV) and an
origin of transfer (oriT; RK2), both of which are flanked by two FRT (FLP recombinase
target) sites. The FRT sites were used to excise the cassette from the cosmid later on
while preparing an in-frame deletion mutant. This is accomplished using an E. coli strain
that expresses the Saccharomyces cerevisiae FLP recombinase enzyme. The apramycin
resistance cassette is used in the first step in preparing a mutant using the Redirect
protocol.  PCR primers were used to amplify the cassette, and the resulting PCR product
was electroporated into an E. coli strain harbouring the blm-containing 12B8 cosmid
(Table 2.2 and Figure 3.1A) and expressing the λ RED proteins.  The blm gene on
Cosmid 12B8 was replaced by the apramycin resistance cassette via homologous
recombination mediated by the λ RED proteins (Figure 3.1 B). The 12B8 cosmid
containing the apramycin cassette was verified by PCR (Figure 3.1; see next section
3.1.1), after which it was conjugated into wt S. clavuligerus. Through homologous
recombination between the mutant cosmid and the chromosome, blm on the wt S.
clavuligerus chromosome was replaced with the apramycin cassette.
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Figure 3.1: Preparation and analysis of the Δblm-AP, Δblm::scar and Δblm::scar ΔampR:: hygR+oriT
cosmids. (A) A schematic representation of the pWE15-based cosmid, 12B8 (Tahlan et al. 2004 b). (B)
Insertions preformed on the 12B8 cosmid.  Primer pairs inside (blue and red arrows) and outside (red
arrows) of blm are shown.  Expected fragment size is dependent on size of insertion and is shown below
each primer pair.  Note that the entire blm gene is not deleted as depicted in the figure (refer to Figure 3.2).
(C) Analysis of the replacement of ampR from 12B8 with hygR+oriT.  Primer pair 3 (orange arrows) anneals
outside of ampR.  Primer pair 4 (light blue arrows) amplifies inside hygR.  The expected fragment size is
dependent on size of insertion and is shown below each primer pair. (D) Gel electrophoresis results of PCR
products from reactions using the primer pairs and cosmid templates described above in (B and C).  In each
case, (L) is the 1 kb ladder and (NC) is the negative control.  Using primer pair 1 (outside primers in red),
PCR resulted in the following expected product sizes: (12B8) 1.6 kb, (Δblm-AP) 1.7 kb, and (Δblm::scar)
~400 bp.  Using primer pair 2 (two reverse primers, red and blue), PCR resulted in the following expected
product sizes: (12B8) no product, (Δblm-AP) 1.3 kb and (Δblm::scar) no product.  Using primer pair 3
(outside primers in orange), PCR resulted in the following expected product sizes: (Δblm::scar) 1 kb and
(ΔampR:: hygR+oriT) 1.6 kb.  Using primer pair 4 (inside primers in light blue), PCR resulted in the
following expected product sizes: (Δblm::scar) no product and (ΔampR:: hygR+oriT) 300 bp.
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This produced the S. clavuligerus blm mutant (Δblm::apraR) with the apramycin
cassette inserted in the reverse orientation in place of blm (Figure 3.1 B).  However, 39 bp
of the 5′ and 3′ ends of blm remained. This mutant was created to examine the potential
of polarity on the expression of orf13 in the Δblm::apraR mutant due to the genetic
overlap present between blm and orf13.  Since the apramycin cassette was inserted in the
direction opposing natural transcription, this mutant had the highest potential to cause
polar effects.
Another blm mutant was created from Δblm::apraR in order to obtain a blm in-
frame mutant that had the least potential to cause polar effects. In order to produce the
Δblm-INF mutant, the 12B8 Δblm-AP cosmid was transformed into the E. coli DH5α
strain containing the BT340 plasmid.  The BT340 plasmid contains the flp gene, encoding
the FLP recombinase enzyme. FLP recombinase catalyzed the recombination between
the FRT sites surrounding the apramycin cassette and caused the excision of the DNA
between them.  This left 39 bp of the beginning and the end of the blm gene as well as an
81 bp scar sequence in place of the original blm gene while maintaining the gene’s
reading frame (Figure 3.2).  This reaction resulted in the production of the 12B8
Δblm::scar cosmid. In order to conjugate the 12B8 Δblm::scar cosmid into S.
clavuligerus, an oriT was required. Since the apramycin cassette was removed, the linked
oriT was also lost in 12B8 Δblm::scar; therefore an oriT needed to be re-introduced into
the cosmid.
Following the same Redirect process as above, PCR primers (pWE15-amp-RD-F
and –R; Table 2.3) were designed to amplify the hygromycin (hyg) resistance cassette
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Figure 3.2: Diagram of the in-frame mutation of blm present in the 12B8 Δblm::scar cosmid and
the S. clavuligerus Δblm-INF mutant.  The first 39 bp of blm including the start codon (STRT),
and the first FRT (FLP recognition target) site comprise the Redirect primer blm-RD-F (Table
2.3), used to create the in-frame mutation.  Both FRT sites (20 bp and 19 bp respectively) and 42
bp of FLP core recombination site comprise the 81 bp “scar” sequence.  The last 39 bp of blm
including the stop codon (STP), and the last FRT site comprise the Redirect primer blm-RD-R.
The start of orf13 overlaps with blm by 4 bp and as such they are likely co-transcribed.
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from pIJ10700 to replace the ampicillin resistance gene (ampR) located on 12B8
Δblm::scar (Figure 3.1 A).  The ampicillin resistance gene is part of the pWE15 cosmid
backbone (Figure 3.1 A). Like the apramycin cassette described above, the hygromycin
cassette contains an oriT and two FRT sites. The knock-in of this cassette effectively
changed the resistance marker on 12B8 Δblm::scar as well as provided an origin of
transfer for conjugation into S. clavuligerus to occur. This newly created cosmid is called
12B8 Δblm::scar::Δamp::hygR.
Once the knock-in of the hygromycin cassette was confirmed, 12B8 Δblm::scar
::Δamp::hygR was conjugated into the S. clavuligerus Δblm::apraR mutant described
above. Through homologous recombination of the genetic regions before and after blm
that are present on both the 12B8 Δblm::scar::Δamp::hygR cosmid as well as the
Δblm::apraR mutant chromosome, the apra-oriT cassette was replaced with the scar
sequence (Figure 3.2). The desired Δblm-INF mutants are identified by the concomitant
loss of all antibiotic resistance and genetic screening across the native blm location.
3.1.1: Verification of all cosmid DNA used to create the blm in-frame mutants
Before transferring the cosmids from E. coli ET1256 to S. clavuligerus, each
cosmid was verified using PCR. All cosmid DNA was verified using the same set of
PCR primers (blm-CONF-F and –R; Table 2.3) as PCR product sizes differed depending
on the cosmid template used. As expected, a 1.6 kb product was observed when the
native 12B8 cosmid DNA was used and a 1.7 kb product was observed when the 12B8
Δblm-AP cosmid DNA was used (Figure 3.1 D primer pair 1).  The PCR product size
change from 1.6 kb to 1.7 kb represents the apramycin cassette in the place of blm (Figure
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3.1 D primer pair 1) making the PCR product larger.  Furthermore, two reverse primers
were used in PCR to validate the reverse orientation of the apramycin cassette in relation
to the direction of blm transcription (Figure 3.1 B). When the apramycin cassette is in the
reverse orientation to transcription, one primer (pIJ773-R) anneals inside the apramycin
cassette in the forward direction.  The second primer (blm-CONF-R) anneals in the
reverse direction outside of the cassette and is the same one used in the other cosmid
confirmation reactions. If the apramycin cassette was in the same orientation as
transcription, these two primers would not produce a PCR product because they would
both anneal in the reverse direction. The backwards orientation of the cassette is
validated due to the production of a 1.3 kb product upon PCR and gel electrophoresis
(Figure 3.1 D primer pair 2). The final cosmid DNA, 12B8 Δblm::scar, produced the
expected ~400 bp product upon PCR and gel electrophoresis (Figure 3.1 D primer pair 1).
This ~400 bp product included the 81 bp scar sequence as well as the flanking DNA
(Figure 3.2). In addition to the replacement of blm on the 12B8 Δblm::scar cosmid,
changes to the ampicillin resistance gene also occurred and therefore required
confirmation.
Before 12B8 Δblm::scar was conjugated into wt S. clavuligerus, the insertion of
the hygromycin cassette (containing the oriT) into the ampicillin resistance gene on 12B8
Δblm::scar was confirmed using PCR.  There is a large size difference between the
ampicillin resistance gene (1 kb) and the hygromycin cassette (1.6 kb).  Hence, a set of
primers (amp-CONF-F/-R) were created to amplify across the ampicillin resistance gene
so the change in PCR product size could be verified (Figure 3.1 C).  Upon PCR and gel
electrophoresis, the size difference noted above was verified (Figure 3.1 D primer pair 3).
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As an added confirmation step, a small 300 bp section of the hygromycin resistance gene
was amplified via PCR (Figure 3.1 D primer pair 4). Both of these PCR results
confirmed that the hygromycin cassette including an oriT was inserted into the ampicillin
resistance gene in 12B8 Δblm::scar, which created the 12B8 Δblm::scar ::Δamp::hygR
cosmid. In conclusion, all PCR product sizes appeared as expected after gel
electrophoresis.
3.1.2: Verification of strains prior to clavulanic acid production analysis
3.1.2.1: Screening for antibiotic resistant phenotypes in the S. clavuligerus mutants
The antibiotic resistance profiles of both mutants were screened to select
individual strains to test and genetically verify. The S. clavuligerus Δblm::apraR mutant
was used to create the Δblm-INF mutant, therefore exconjugates were screened for
mutants containing apramycin resistance (stemming from the apramycin cassette).
Genomic DNA from confirmed strains was then used in PCR reactions to verify the
replacement of blm with the apramycin cassette (see next section 3.1.2.2).
The S. clavuligerus Δblm::apraR mutant was used to create the S. clavuligerus
Δblm-INF mutant.  Once this mutant was created, the Δblm-INF mutant went through two
sets of antibiotic resistance screening.  The first round occurred after the conjugation of
the 12B8 Δblm::scar::Δamp::hygR cosmid into the S. clavuligerus Δblm::apraR mutant.
These exconjugates were screened for kanamycin resistant strains that contained the
entire scar cosmid integrated by a single crossover. The kanamycin resistance stems from
the kanamycin resistance gene (KanR), which is present on the pWE15 cosmid backbone
(Figure 3.1 A).  These kanamycin resistant strains were isolated on antibiotic free
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medium before being screened for the loss of both kanamycin and apramycin resistance.
The antibiotic sensitive clones were the desired S. clavuligerus Δblm-INF mutants.
Genomic DNA from these confirmed strains was then used in PCR reactions to verify the
replacement of blm with the scar sequence (see next section 3.1.2.2).
3.1.2.2: PCR verification of the S. clavuligerus blm mutants
Using the same primer pair (blm-CONF-F and -R) and the same reaction
conditions as above, all mutant S. clavuligerus strains were confirmed through PCR using
genomic DNA as a template (Figure 3.3 A). Since the cosmids above (section 3.1.1)
were used to create the S. clavuligerus mutants, the sizes of the confirmation products are
the same. As a control, wt S. clavuligerus genomic DNA was used as template, which
produced the expected 1.6 kb product (Figure 3.3 B primer pair 1). When genomic DNA
from the Δblm::apraR mutant was used, a 1.7 kb product was observed (Figure 3.3 B
primer pair 1).  The reverse orientation of the apramycin cassette was also confirmed
using genomic DNA (Figure 3.3 B primer pair 2).  The Δblm::apraR mutant was the only
reaction expected to produce a product (Figure 3.3 B primer pair 2).  This confirms the
reverse orientation of the cassette in the genomic DNA of the Δblm::apraR mutant. When
genomic DNA of the ∆blm-INF mutant was used, the expected ~400 bp product was
observed (Figure 3.3 B primer pair 1).  To confirm that the ∆blm-INF mutant was
genetically correct and in-frame, the ~400 bp PCR product was cloned into pGEMT-Easy
and sent for sequencing.  According to the results (Supplementary Figure 1), the 81 bp
scar sequence including both FRT sites and 39 bp of the beginning and end portions of
blm (Figure 3.2) were present as expected.
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Figure 3.3: Preparation and analysis of the S. clavuligerus Δblm::apraR and Δblm-INF mutants. (A) The
insertions performed on wt S. clavuligerus.  Primers used for mutant verification which anneal to regions
surrounding blm (red arrows) or within the apra cassette (blue arrow) are shown. Expected fragment size is
dependent on size of insertion and is shown below each primer pair.  Note that the entire blm gene is not
deleted as depicted in the figure (refer to Figure 3.2). (B) Gel electrophoresis results of PCR products from
reactions using the primer pairs and genomic templates described above in (A).  In each case, (L) is the 1 kb
ladder and (NC) is the negative control.  Using primer pair 1 (outside primers in red), PCR resulted in the
following expected product sizes: (WT) 1.6 kb, (Δblm::apraR) 1.7 kb and (Δblm-INF) ~400 kb.  Using
primer pair 2 (two reverse primers, red and blue), PCR resulted in the following expected product sizes:
(WT) no product, (Δblm::apraR) 1.3 kb and (Δblm-INF) no product.
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Negative control reactions using sterile H2O instead of template DNA were
completed using both primer pair 1 and primer pair 2.  Both negative control reactions did
not produce PCR products so contaminating DNA was not present in any of the reactions.
3.2: Complementation of blm mutants to assess for polar effects
Previous studies have demonstrated that when either blm or orf13 are mutated, CA
production drastically decreases (Li et al. 2000; Jensen et al. 2004).  Accordingly, both
the Δblm::apraR mutant and ∆blm-INF should not produce the metabolite whereas the wt
strain should. Complementation studies were carried out to verify these phenotypes as
well as to determine if the mutation of the blm gene has a polar effect on orf13.  CA
production was first verified via bioassay against K. pneumoniae before the same
supernatants were analyzed via HPLC. Each strain was grown in SA medium for up to
96 hours, and samples were collected as described in section 2.6.1.  Zones of inhibition
were observed around discs infused with supernatants from wt S. clavuligerus and wt +
pHM11a cultures (Table 3.1, Figure 3.4).  Since the plasmid pHM11a is used as the
expression vector for all complementations, the empty vector was used as a control to
show that did not have a significant effect on the strain’s ability to produce CA.
Supernatants from the Δblm::apraR, ∆blm-INF and orf12::apra (Jensen et al. 2004)
mutants did not produce zones of inhibition (Table 3.1, Figure 3.4).  All three of these
results are to be expected because in each strain blm is disrupted.  Additionally, when
pHM11a is introduced into each strain, CA production was not restored; therefore, the
expression vector has no effect on their phenotype, which was to be expected (Table 3.1,
Figure 3.4).  CA production is restored in the three non-producing mutants when blm was
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Time-point 48 hours 96 hours
Strain Culture
Replicate 1 2 1 2
Wt 25 23 28 27
wt+pHM11a 13 19 21 25
wt+pH:blmSC 25 20 29 25
∆blm::apraR 0 0 0 0
∆blm::apraR+pHM11a 0 0 0 0
∆blm::apraR+ pH:blmSC 26 20 29 24
orf12::apra 0 0 0 0
orf12::apra+pHM11a 0 0 0 0
orf12::apra+ pH:blmSC 21 19 25 22
∆blm-INF 0 0 0 0
∆blm-INF+pHM11a 0 0 0 0
∆blm-INF+ pH:blmSC 20 20 22 20
∆blm-INF+ pH:blm-flag 21 15 22 18
∆blm-INF+ pH:blmSF 0 0 0 0
∆blm-INF+ pH:blmSV 0 0 0 0
Table 3.1: Diameter (in mm) of zones of inhibition of Klebsiella pneumoniae by
clavulanic acid containing culture supernatants from two culture replicates of various
mutant strains of Streptomyces clavuligerus
“0”= zone of clearing not observed, orf12::apra = S. clavuligerus blm insertional mutant
strain (Jensen et al. 2004)
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Figure 3.4: Bioassay results for the detection of CA in liquid culture supernatants from various S.
clavuligerus strains.  Strains include wt, Δblm::apraR, Δorf12::apraR (Jensen et al. 2004) and Δblm-INF
containing either pHM11a, pHM11::blmSC, pHM11a::blm-flag or no plasmid (-).  Each culture was grown
for 48 and 96 hours in SA medium.  Image shows results for one of the two replicates completed for each
culture and incubation period.
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re-introduced into the mutants (Table 3.1, Figure 3.4).
Since the zones of inhibition were larger at the 96 hour time point, these
supernatants were chosen to be analyzed by HPLC to confirm the presence of CA in the
sample. Supernatants from two replicates of each strain were prepared as described in
section 2.6.2 and CA production was determined by observing peak areas absorbing at
311 nm. Five CA standards with the following concentrations of 0.01, 0.13, 0.25, 0.38
and 0.5 μg/μl were used as positive controls and to create a standard curve
(Supplementary Figure 2).  The standard curve was used to determine the CA
concentration within each supernatant.  Derivatized supernatants from the following
strains showed a detectable peak absorbing at 311 nm at ~ 10 minutes: wt, wt+pHM11a,
wt+pH:blmSC, ∆blm::apraR +pH:blmSC, blm::apraR+pH:blmSC, ∆blm::INF+pH:blmSC,
and ∆blm::INF+pH:blm-FLAG (discussed later in section 3.4.3).  Derivatized
supernatants from all mutant strains containing a knockout of blm (∆blm::apraR,
orf12::apra, and ∆blm::INF) did not produce a signal absorbing at 311 nm.  All strains
containing the empty expression vector pHM11a displayed the same phenotype
(producing/non-producing) as their parent strain, which do not contain the vector.
However, the wt strain that contained pHM11a not produce the same level of CA as the
wt type strain on its own.  The vector, pHM11a, had an effect on the production of CA
that lead to the decrease in CA production. Nonetheless, the results of the HPLC analysis
concur with the results of the bioassays done above.
The CA production levels in the various strains were normalized using dry cell
weight (Supplementary Table 1) to account for the differences in growth between the
strains. Concentrations of CA calculated using the CA standard curve (Supplementary
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Figure 2) were divided by the dry cell weights of each replicate.  This resulted in a
concentration of CA produced by each mg of cells in a culture, allowing the CA
concentrations to be compared across all strains (Figure 3.5).
3.3: Alignment of Blm from S. clavuligerus, S. viridis and S. flavogriseus
The amino acid sequences of Blm from S. clavuligerus, S. viridis and S.
flavogriseus have previously been aligned (Valegard et al. 2013). As mentioned
previously, the Blm-like protein from S. flavogriseus has ~60 % amino acid identity and
the Blm-like protein from S. viridis has 52 % amino acid identity with their orthologue in
S. clavuligerus. Nonetheless, further focus on the hypothesized functional domains and
CA binding locations may provide insight into whether or not the Blm-like proteins from
the other two species will complement the S. clavuligerus ∆blm-INF mutant.  Valegard et
al. (2013) highlighted several key residues of Blm that are likely to compose its active
site, CA binding pockets and catalytic motifs.  Of particular interest are the three motifs
that are characteristic of serine β-lactamase active-sites: SXXK, SDN and KTG.  These
domains contain the characteristic catalytic tetrad of Ser1/Ser2 (Tyr)/Lys1 (His)/Lys2,
which has been found in S. clavuligerus Blm as Ser173/Ser234/Lys176/Lys375 (Figure
3.6, dark blue and red boxes).  In the S. viridis and S. flavogriseus Blm homologues, these
motifs (Figure 3.6, red boxes) are almost identical to the S. clavuligerus Blm motifs.
Most importantly, the catalytic tetrad residues are conserved (Figure 3.6, dark blue and
red boxes).  According to Valegard et al. (2013), the most important catalytic residue of
the tetrad is Ser173, since mutation of this residue resulted in a 100-fold reduction in
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Figure 3.5: Clavulanic acid production by each strain in this study after 96 hours of incubation. Bar graph
of the average concentration of CA produced by each strain used in this study.  Concentrations (μg/μl) were
calculated by comparison of HPLC determined values against a standard curve of known CA concentrations
(Supplementary Figure 2).  These values were then standardized using the dry cell weight (mg) determined
for each culture.  Concentrations and dry cell weights were determined in duplicate (n=2) for each strain.
Strains with no bars on the chart did not produce detectable levels of CA.  This experiment included
orf12::apra (Jensen et al. 2004).  Error bars indicate the standard error of the mean.
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Figure 3.6: Protein alignment of Blm from S. clavuligerus, S. flavogriseus, and S. viridis with important residues highlighted.  Three motifs that
are characteristic of serine β-lactamase active-sites are enclosed in red boxes. Conserved residues important for catalytic activity in serine β-
lactamases are indicated by dark blue boxes. Pink boxes highlight residues that comprise the Blm active site of S. clavuligerus.  The residues that
make up the hydrophobic cleft where a proposed second molecule of CA can bind (Valegard et al. 2013) are located in light blue boxes.  The
yellow box surrounds the Arg 308 residue of S. flavogriseus. This is a proposed silent mutation in the blmSF gene used in this study. Labels on
the side separate the N and C terminal domains.  Alignment created using the BOXSHADE software (Hofmann & Baron, Institute Pasteur,
France).
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S. clavuligerus Blm esterase activity, and this residue is conserved in the S. viridis and S.
flavogriseus Blm homologues (Figure 3.6).
Valegard et al. (2013) also suggest that one Blm molecule binds two CA
molecules.  One CA molecule hydrogen binds to the active site, which is composed of the
Tyr359, Lys89 and Arg418 residues (Figure 3.6, pink boxes).  The other CA molecule
binds in a hydrophobic cleft made up by His84, Trp91, Leu362, Leu415, Arg418, and
Ala422 (Figure 3.6, light blue boxes).  All three residues that make up the Blm active site
are conserved in S. viridis and S. flavogriseus, but only two (Trp91 and Arg418) residues
from the second site are conserved in these species.
3.3.1: Complementing the ∆blm-INF mutant with blm-like genes from S. viridis and
S. flavogriseus
When the CA-like gene clusters were found in S. viridis and S. flavogriseus, they
were determined to be silent clusters as studies were unable to detect any CA production
by the organisms (Alverez-Alverez et al. 2013).  The study determined that the lack of
CA production in both organisms was likely due to either low or complete lack of
expression of several genes essential for CA production, including blm.  To determine if
the Blm-like proteins from S. viridis and S. flavogriseus are similar in function to Blm
from S. clavuligerus, they were cloned into the expression vector pHM11a.  The resulting
plasmids were conjugated into the ∆blm-INF mutant and the final mutant’s ability to
produce CA was tested.
The blm gene from S. clavuligerus and the blm-like genes from S. viridis and S.
flavogriseus were amplified via PCR using the primers and program described above
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(section 2.4.1.2) before being ligated into pGEMT-Easy.  Once cloned into pGEMT-Easy,
the blm-like genes were sequenced before the genes were excised from pGEMT-Easy and
cloned into the expression plasmid pHM11a (section 2.4.2.2). The blm-like genes were
sequenced again in pHM11A before these final plasmids were introduced into the ∆blm-
INF mutant.
The final sequencing results (Supplementary Figures 3, 4, 5) were aligned with
the published sequence (S. clavuligerus: AY258009, S. viridis: CP001683, S.
flavogriseus: CP002475) of each gene.  It was determined that blm from S. clavuligerus
and S. viridis did not contain any mutations, whereas blm from S. flavogriseus contained a
single point mutation (CT) at nucleotide position 924 (Supplementary Figure 5).  When
translated, the mutated codon results in the same amino acid (Figure 3.6, yellow box),
therefore the mutation may be considered silent.
3.3.2: CA production analysis of ∆blm-INF strains containing the blm-like genes
from S. viridis and S. flavogriseus
Bioassays and HPLC analysis (section 2.6) were performed on supernatants from
these mutant cultures to observe whether CA production is rescued by these foreign blm-
like genes. CA production in S. viridis and S. flavogriseus was previously tested in the
defined SA medium and the results were negative (Alverez-Alverez et al. 2013).  CA
production was also tested in the S. clavuligerus ∆blm-INF mutant (section 3.2) with
negative results due to the deletion of the blm gene. CA production of the ∆blm-INF
mutant containing the blm-like genes was first verified via bioassay against K.
pneumoniae before the same supernatants were analyzed via HPLC. Duplicate cultures
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of each strain were grown in SA medium for up to 96 hours and samples were collected
as described in section 2.6.1. Zones of inhibition were not observed around discs infused
with supernatants from either ∆blm-INF + pH:blmSF or ∆blm-INF + pH:blmSV (Table 3.1).
The bioassay and HPLC analyses for these strains were conducted simultaneously with
the bioassay and HPLC analyses completed in section 3.2. Accordingly, the control
strains S. clavuligerus wt, wt+pHM11a, ∆blm-INF and ∆blm-INF+pH:blmSC were tested
at the same time. Derivatized supernatants from ∆blm-INF + pH:blmSF, ∆blm-INF +
pH:blmSV and ∆blm-INF did not produce a signal absorbing at 311 nm by the 10 minute
mark, while wt, wt+pHM11a and ∆blm-INF+pH:blmSC did (Figure 3.5).  The results of
the HPLC analysis concur with the results of the bioassays completed above.
3.3.3: Examination of codon usage between S. clavuligerus, S. flavogriseus and S.
viridis
To examine both Blm-like proteins further, each amino acid sequence from S.
flavogriseus and S. viridis as well as Blm from S. clavuligerus was scanned against the
known codon usage bias of S. clavuligerus (Nakamura et al. 2000) using the Graphical
Codon Usage Analyser (Fuhrmann et al. 2004).  This program returned a graphical
representation (Supplementary Figure 6, 7, 8) depicting the relative adaptiveness of each
codon used in the Blm-like proteins to the codon usage bias of S. clavuligerus. The Blm-
like protein from S. viridis exhibited the most difference in codon usage (12.81%).  The
difference occurred in the codons used to code for four different amino acids.  The codons
used by S. viridis are all still used in S. clavuligerus but at varying rates for each
(Supplementary Figure 6). The Blm-like protein from S. flavogriseus exhibited the least
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difference in codon usage (5.09%) when compared to the S. clavuligerus codon usage
(Supplementary Figure 7).  The difference occurred in the codons used to code the amino
acids arginine and proline; however, the codons used by S. flavogriseus are still
frequently used in the S. clavuligerus genome at high rates (Supplementary Figure 7). To
maintain consistency, Blm from S. clavuligerus was screened against its own codon bias
and a difference of 6.61% was found (Supplementary Figure 8).  The difference was in
the codons used for the two amino acids alanine and proline.  Of special note, the same
codon was used for proline (CCC) in Blm from S. clavuligerus, and the Blm-like protein
in S. flavogriseus but this codon (CCC) is not the most frequently used one for proline in
the S. clavuligerus genome (Supplementary Figure 7 and 8). As a result, Blm from S.
clavuligerus and Blm-like protein from S. flavogriseus only differ in codon usage by one
codon.
3.4: Examination of the cellular localization of Blm
In order to determine the cellular location of Blm in S. clavuligerus, a short
polypeptide sequence, known as the FLAG tag (Hopp et al. 1988), was added to the C-
terminal end of each protein. The FLAG tag was engineered into the reverse primers
(Table 2.3) used to amplify blm as well as two control genes, blip and ccaR. Once
translated, the FLAG-tagged proteins were transported to their active sites either inside or
outside the cell. Their cellular localization was determined by collecting different
fractions of cell culture and performing western analysis with anti-FLAG antibodies.
Since all FLAG-tagged genes were transferred into wt S. clavuligerus in pHM11a, their
transcription was regulated by the constitutive ermE* promoter (ermEp*).
80
Before being conjugated into wt S. clavuligerus, all three genes were sequenced in
pHM11a to ensure each was free of mutation and contained the C-terminal FLAG
sequence. Sequencing results (Supplementary Figures 9, 10, 11) were entered into the
bioinformatic analysis program Geneious, and aligned with the published sequence of
each gene.  It was determined that blm, ccaR, and blip did not contain any mutations and
each contained a C-terminal FLAG tag.
3.4.1: Analysis of CA production from S. clavuligerus ∆blm-INF +pHM11a::blm-
FLAG
The FLAG tagged version of blm was introduced into the S. clavuligerus ∆blm-
INF mutant to ensure that this version of blm is biologically active enough to restore CA
production in the ∆blm-INF mutant.  By doing this, we can confirm that Blm is located in
its natural sub-cellular location because it is either biologically active or not. Bioassays
against K. pneumoniae and HPLC analysis of culture supernatants were completed to
ensure that the S. clavuligerus ∆blm-INF +pH:blm-FLAG strain was able to produce CA.
Bioassays were completed with duplicate cultures of each strain (as described above in
section 2.6.1) and supernatants from the 48 hour and 96 hour time point were tested.  It
was found that at both the 48 and 96 hour time points, the ∆blm-INF +pH:blm-FLAG
strain was capable of producing CA (Table 3.1, Figure 3.4). Zones of inhibition were
observed surrounding disks that were infused with culture supernatants from this strain.
HPLC analysis was completed on 96 hour supernatant of ∆blm-INF +pH:blm-
FLAG due to increased CA production at this time point as shown by the bioassay results
(Table 3.1, Figure 3.4).  Analysis was conducted on duplicate culture replicates and a
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peak representing CA absorbed at 311nm by ~10 minutes in both replicates
(Supplementary Table 2). The area under the CA peak was compared to the CA
standards graph (mentioned in section 3.2) and CA concentration was determined for
each replicate.  The dry cell weight of 1 ml of each ∆blm-INF +pH:blm-FLAG culture
replicate was determined as described in section 2.3.9.  The CA concentrations of each
replicate were determined and put into the graph of the CA concentrations of all mutants
(Figure 3.5) so that all could easily be compared.
3.4.2: Determination of a time point for protein extraction
According to the literature, CA production is well established after 48 hours
incubation in SA medium and peak production occurs around 96 hours of growth
(Paradkar et al. 1996).  However, there was no significant size difference between the
zones of inhibition at the 48 and the 96 hour time points during bioassay analysis.  As a
result, the 48 hour time point was chosen for protein isolation to determine the sub-
cellular location of Blm during active CA production.  The 96 hour time point was not
selected due to the increased likelihood of cell lysis at the later time point, which would
release intercellular FLAG-tagged proteins into the supernatant and produce conflicting
results.
3.4.3: Localization of Blm, CcaR and Blip in S. clavuligerus through the use of
western blotting
Protein was extracted from 48 hour cultures of wt+pHM11a, wt+pH:blm-FLAG,
wt+ pH:ccaR-FLAG and wt+pH:blip-FLAG using two different methods. The first
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method extracted cytoplasmic proteins by subjecting mycelial pellets to sonication,
resulting in crude cellular lysates.  The second method extracted secreted proteins from
supernatant of the same cultures above, through a salting out process using ammonium
sulfate. One culture of each strain was used for both methods, as one method extracts
cytoplasmic protein and the other extracts secreted proteins.
Western analysis using FLAG-specific polyclonal antibodies was carried out to
investigate the sub-cellular localization of Blm in comparison to the known control
proteins CcaR and Blip.  Salted out supernatant protein (50 μg) and cytoplasmic protein
(20 μg) from wt+pHM11a, wt+pH:blm-FLAG, wt+ pH:ccaR-FLAG and wt+pH:blip-
FLAG cultures were separated on 12% SDS-PAGE and transferred to separate PVDF
membranes. After overnight membrane blocking, the membranes were incubated with
anti-FLAG antibody and then incubated with secondary antibodies. The membranes were
developed with chemiluminescence reagents and imaged with a digital imaging system.
A standard curve (Supplementary Figure 12) was created for each membrane to be able to
accurately determine the weights of each protein in comparison to the molecular weight
ladders.
In the western blot analysis of cytoplasmic proteins, two signals were detected in
the lanes containing cytoplasmic proteins from the wt+pH:ccaR-FLAG and wt+pH:blm-
FLAG cultures (Figure 3.7 B).  Using the standard curve generated (Supplementary
Figure 12) and ImageJ software, the molecular weight of the protein from the
wt+pH:ccaR-FLAG culture was determined to be 34 kDa and the protein from the wt+
pH:blm-FLAG culture was determined to be 54 kDa.  The size of CcaR is 5 kDa larger
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Figure 3.7: Analysis of western blots depicting the sub-cellular location of FLAG-tagged Blip, CcaR and
Blm in S. clavuligerus. A) Western blot using anti-FLAG antibodies against proteins (50 μg) salted out
from the supernatants of wt+pH:blip-FLAG (Blip), wt+pH:blm-FLAG (Blm), wt+pH:ccaR-FLAG (CcaR)
and wt+pHM11a (WT).  (L1), 5 μl of PiNK Plus pre-stained protein ladder; (Blip), a band at the expected
size is present; (Blm) no banding present ; (CcaR) no banding present; (WT) no banding present; (L2), 5
μl of Thermo Scientific PageRuler Plus Prestained Protein Ladder. Sizes of marker bands in L2 are noted
in kDa along the right. B) Western blot using anti-FLAG antibodies against proteins (20 μg) fractionated
from the cell lysate of wt+pH:blip-FLAG (Blip), wt+pH:blm-FLAG (Blm), wt+pH:ccaR-FLAG (CcaR)
and wt+pHM11a (WT).  (L1), 5 μl of PiNK Plus pre-stained protein ladder; (Blip), no banding present;
(Blm), a band at the expected size is present; (CcaR), a band of the expected size is present; (WT), no
banding present; (L2), 5 μl of Thermo Scientific PageRuler Plus Prestained Protein Ladder.  Sizes of
marker bands in L2 are noted in kDa along the right. C) A table depicting the experimental and expected
molecular weights for Blm, CcaR and Blip.  The percent error between the experimental and expected
weights is calculated while taking into account the molecular weight of the FLAG tag.  Experimental
weights were calculated using the standard curve generated (Supplementary Figure 12) and the expected
weights were determined based on the published nucleotide sequence for each gene and translating them
to their amino acid sequence (see section 2.7.4). The molecular weight (1 kDa) of the FLAG tag was
added to the expected weight and this value (theoretical) along with the experimentally determined value
was used to calculate percent error.
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than the published size 29 kDa.  The size of Blm is in agreement with the published size
range of 50- 55 kDa that was purified from E. coli (Valegard et al. 2013).
In the western blot analysis of supernatant proteins, only one signal was detected
in the lane containing supernatant proteins from the wt+pH:blip-FLAG culture (Figure
3.7 A). Using the standard curve generated (Supplementary Figure 12) and ImageJ
software, the molecular weight of the protein from the wt+pH:blip-FLAG culture was
determined to be 18 kDa.  This size is in agreement with the published size range of Blip,
16.9-18 kDa (Doran et al. 1990). Signals were not observed in other lanes in this
analysis.  This was to be expected as the two other FLAG-tagged proteins were
previously found in the cytoplasmic protein analysis. In addition, cell lysis was not a
factor in the harvested cultures as additional signals in the Blm and CcaR lanes were not
detected.
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Chapter 4: Discussion
This study explored the polarity of blm mutants to determine if mutation of this
gene leads to polar effects on the expression of downstream genes.  This was done
indirectly by the preparation of two mutants and subsequent complementation studies
using native blm and the blm-like genes from S. flavogriseus and S. viridis.  Additionally,
this study also aimed to look at the cellular localization of the Blm protein in S.
clavuligerus, as this information would provide insights into its biological function in CA
production.  The following sections discuss the major findings of this study as well as
highlight areas in need of further investigation.
4.1: The creation and analysis of the S. clavuligerus Δblm mutants
When the insertional mutants RFL 5-56 (Li et al. 2000) and orf12::apra (Jensen et
al. 2004) were first analyzed, it was found that the production of CA was completely
blocked in these mutants.  More recently, it has come to light that the genetic sequences
of orf13, blm and orf14 overlap each other (Figure 1.5) and orf13/blm are co-transcribed
while orf14 is transcribed in the opposing direction (Mellado et al. 2002). As a result, the
original thought was that the blm/orf13 transcript may share the same ribosome binding
site (RBS) and may be co-translated as well. Due to the overlapping nature, the
insertional mutants created in previous studies may display polar effects on downstream
genes as the mutant proposed in the Jensen study (2004) was not complemented.
Therefore, the current study created a mutant (Δblm::apraR) by replacing blm with an
apramycin cassette in reverse orientation.  This was an attempt to produce polar effects
and determine whether transcriptional and translational coupling is occurring between
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blm and orf13.  An in-frame blm mutant was later prepared using the Δblm::apraR mutant
for complementation studies with blm-like genes from S. viridis and S. flavogriseus.
Both the Δblm::apraR and the Δblm-INF mutant were created using the Redirect
method (Gust et al. 2003).  The replacement of blm with the apramycin cassette in the
current study removes the native blm gene from the chromosome.  In addition, the
apramycin cassette is placed in the reverse orientation to the natural direction of
transcription of blm and orf13.  Having the cassette orientated in the direction opposing
natural transcription could cause clashes between RNA and DNA polymerases leading to
replication fork stalling or aborted chromosomal DNA replication (Rocha 2002).  This
would be particularly troublesome as bacteria exhibit gene orientation bias where highly
expressed genes are present on the leading strand of replication in order to co-orient
polymerases, thus reducing stalling and collisions (Rocha 2002).  The stalling or abortion
of transcription in the area of blm would have profound genetic effects on this mutant due
to the co-transcription and possible co-translation of blm and orf13. In addition, there is
the possibility of antisense mRNA binding to the natural promoter driven mRNA
transcript and inhibiting translation.  Due to the opposite orientation of the apramycin
cassette, antisense mRNA transcript production is possible (Camblong et al. 2009; Lasa et
al. 2012).  Since the Δblm::apraR mutant retained a portion of the 5′ region of blm (start
codon and 39 bp of the beginning of blm as in Figure 3.2), both the promoter driven
mRNA and the antisense mRNA transcripts contain the same region.  As a result,
complementary base pairing is possible, that leads to the inhibition of translation through
physical obstruction of the translation machinery (Brophy and Voight 2016) or
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degradation by RNases.  These complications would be described as causes of
downstream polarity.
The mutation of blm in Δblm-INF and ∆blm::apraR lead to the complete cessation
of CA production (Figure 3.4 and 3.5; Table 3.1). However, the existence of genetic
polarity in the ∆blm::apraR mutant can only be determined from complementation studies
using blm on its own.  Since both blm and orf13 are crucial for the production of CA (Li
et al. 2000; Jensen et al. 2003), the mutation of blm whether it displays polar effects or
not would produce the same results: complete cessation of CA production.
4.2: Complementation of the of the S. clavuligerus Δblm mutants
Complementation strains were created by introducing a native copy of the S.
clavuligerus blm gene into all of the mutant strains as well as wt S. clavuligerus.  The
Streptomyces integrative expression vector pHM11a (Motamedi et al. 1995) was used to
shuttle a native copy of blm into each mutant strain.  In pHM11a, blm is under the control
of the strong constitutive ermEp* promoter; therefore, it is constitutively expressed.
Complementation studies showed that both mutants could be successfully
complemented by blmsc (Figure 3.4 and 3.5; Table 3.1). Since pHM11a had an effect on
CA production (Figure 3.4 and 3.5; Table 3.1), the level of complementation for each
strain can only be compared to the wt+pHM11a control strain. Based on this comparison,
both Δblm mutants complemented completely. It is not an uncommon phenomenon for
large expression vectors to have an effect on specialized metabolite production in
Streptomyces (Tahlan personal communication). The vector, pHM11a, is a very large
(9.7 kb) plasmid that is energetically expensive for the cell to maintain.  As well, this
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plasmid integrates into the chromosome at the mini-circle att site (Motamedi et al. 1995),
which is located away from the CA genetic cluster and the native blm position.  Both of
these conditions could be causing the decrease in CA production observed in strains
containing the pHM11a vector.
Due to the compete complementation of both Δblm mutants, there is no
transcriptional or translational polarity in either mutant and there are no other factors
(besides blm) affecting their function. Accordingly, it can be concluded that the
positioning of the apramycin cassette in the ∆blm::apraR mutant does not affect
expression of orf13.
Upon further examination of the orf13 upstream region, a potential Shine-
Delgarno (SD) sequence (GGAGAAG) was located 13 nt upstream from orf13’s start
codon.  This sequence shows similarity to the consensus Streptomyces SD sequence
(GGAGG) as well as a few others that are less common (Strohl 1992).  This potential
RBS explains why the ∆blm::apraR mutant does not display transcriptional or
translational polarity. The RBS is conserved in both Δblm mutants as 39 nt of both the
beginning and the end regions of blm remained in each mutant.
4.3: The blm-like genes from S. flavogriseus and S. viridis do not complement the
Δblm-INF mutant
In previous studies, two putative CA producers were found: S. viridis and S.
flavogriseus (Jensen 2012).  Both organisms contain the entire CA gene cluster as well as
orthologues of nocE, blip and pcbR that are found in S. clavuligerus.  Efforts to try to
either activate production or heterologously express the CA cluster in these organisms
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have been unsuccessful (Jensen 2012) and CA production requirements have yet to be
determined (Alvarez-Alvarez et al. 2013).
As well as having high nucleotide identity (blmSC shares 71% and 69% nucleotide
identity with blmSF and blmSV respectively), blm in these organisms maintains its
overlapping nature (Figure 1.5) with the surrounding orf13 and orf14 orthologs.  Previous
studies have shown that blm is severely under expressed in S. flavogriseus and therefore
is considered silent (Alvarez-Alvarez et al. 2013).  With blm being essential to the
production of CA in S. clavuligerus, its silent nature in S. flavogriseus could be the reason
this organism is unable to produce CA.  As a result, this study aimed to determine how
similar the Blm-like protein from either of these species is to Blm from S. clavuligerus.
Bioinformatics analysis and experimentation were conducted to determine whether the
similarity was sufficient enough to restore CA production in the S. clavuligerus Δblm-INF
mutant created in this study.
The alignment of the amino acid sequences of Blm from S. clavuligerus, S. viridis
and S. flavogriseus, revealed the conservation of several key residues proposed by
Valegard et al. (2013).  The three motifs that are characteristic of serine β-lactamase
active-sites, SXXK, SDN and KTG (Figure 3.6, dark blue and red boxes), are almost
exclusively conserved in S. viridis and S. flavogriseus when compared to the same sites in
S. clavuligerus. More importantly, the catalytic tetrad outline by Valegard et al. (2013)
including the most essential residue of the tetrad (Ser173) is completely conserved.  As
well, all three residues that make up the Blm active site (Figure 3.6, pink boxes) are
conserved in S. viridis and S. flavogriseus, but only two residues (Figure 3.6, light blue
boxes) from the second CA binding site are conserved.
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According to the bioinformatics analysis above, it seems logical that the blm-like
genes from the other two species would complement the S. clavuligerus Δblm-INF mutant
and restore its CA production.  Nevertheless, neither the blm-like gene from S. viridis nor
S. flavogriseus restored CA production in the S. clavuligerus Δblm-INF mutant.  Both
bioassay and HPLC analysis results revealed no detectable CA production by either
mutant (Table 3.1, Figure 3.5).  Almost all residues highlighted by Valegard et al. (2013)
are conserved amongst the three species except in regards to the second CA binding site
where only two of the six total residues are conserved.  Valegard et al. (2013) proposed
that the two conserved residues may act as gatekeepers for the active site.  It is possible
that the binding of the second CA molecule may be required to activate or release the first
CA molecule from the active site.  If the second CA binding site in S. flavogriseus and S.
viridis does not contain the correct residues to bind a second molecule of CA, it is
possible that Blm could be bound to one molecule of CA and remain permanently
inactive in the Δblm-INF mutant.  It is also possible that the proposed CA gene cluster in
S. flavogriseus and S. viridis does not synthesize CA but something related to or similar
to CA.  If this were the case, the second CA binding site in Blm from S. flavogriseus and
S. viridis may bind more specifically to a CA related molecule whereas the active site
contains more general catalytic residues to perform the same function on the CA related
molecule.  Additionally, even though most of the catalytic motifs are conserved in the
three Blm proteins, overall there are sequence differences between them that could cause
the Blm-like proteins from S. flavogriseus and S. viridis to be different enough that they
cannot complement the S. clavuligerus Δblm-INF mutant.  In this case, it is possible that
the S. flavogriseus and S. viridis CA gene clusters are evolutionary precursors to the S.
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clavuligerus CA gene cluster or they are descendants of the S. clavuligerus CA gene
cluster that have now become inactive.
Streptomyces exhibit a strong preference over which codon to use for each amino
acid (Gustafsson et al. 2004).  This is known as codon usage bias and occurs in all
bacteria but is most extreme in high GC bacterial genomes.  Codon usage bias is the
single most important factor in prokaryotic gene expression because preferred codons
correlate with the availability and abundance of the related tRNAs within the cell
(Chaney and Clark 2015).  This could pose potential problems during heterologous gene
expression as could be the case in this study. Accordingly, the codon usage of each Blm-
like protein studied (including Blm from S. clavuligerus) was compared against the
documented codon usage present in S. clavuligerus.  The relative adaptiveness of each
Blm-like protein was determined through the use of the Graphical Codon Usage Analyser
(Fuhrmann et al. 2004) and the mean difference in codon usage was reported.  The mean
difference was very low and similar (6.61% and 5.09% respectively) between Blm from
S. clavuligerus and the similar protein in S. flavogriseus (Supplementary Figure 7 and 8).
This is to be expected as both organisms are from the same genus and therefore have
similar codon usage.  The largest mean difference in codon usage came from the Blm-like
protein in S. viridis, which is to be expected as S. viridis is more distantly related.  In spite
of its ancestry, the mean difference in codon usage between S. clavuligerus and S. viridis
Blm is relatively low at only 12.81% (Supplementary Figure 6).  In short, it is not likely
that the codon usage bias exhibited by S. clavuligerus is a factor in the dormancy of the
Blm-like proteins in the Δblm-INF mutant.
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In this study, a point mutation was found in the blm-like gene from S.
flavogriseus.  It occurs in the third position of the nucleotide codon triplet
(Supplementary Figure 5) and produces a silent mutation.  As a result, the amino acid
(Arg 308) translated from that codon remains the same (Figure 3.6, yellow box).  In
addition, Arg 308 has not yet been highlighted as a residue important for catalytic
function and is not in close proximity to already highlighted residues.  Regardless, there is
a large difference in the codon usage frequency between the original triplet (47.2 per
thousand) and the mutated triplet (5.5 per thousand) (Nakamura et al. 2000).  This
difference may pose a problem for the translation of the codon to its amino acid.
4.4: Blm is located in the cytoplasm of the cell
It is widely agreed that Blm must have an important enzymatic function inside the
cell as it is integral to the production of CA (Li et al. 2000; Jensen et al. 2004; de la
Fuente et al. 2002).  Blm is considered to be part of the “late steps” of CA production and
some predict that it may be responsible for the epimerization step during the conversion
of clavaminic acid to CA (Jensen et al. 2012; Valegard et al. 2013).  On the other hand, if
Blm plays any sort of role like its namesake, a β-lactamase, it would be secreted and be
active outside of the cell (Drawz and Bonomo 2010).  Therefore, determining the cellular
location of Blm can help focus the functional possibilities because enzymes found within
cell have different functions than ones found outside of the cell.
Through the use of FLAG tags, anti-FLAG antibodies and western analysis, the
cellular location of the active Blm protein was determined. Blm was found to be
localized to the cytoplasm of the cell and not excreted extracellularly, ruling out the
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possibility of an extracellular function. Blm does not have a predicted secretion signal;
however, this study aimed to completely rule out an extracellular function since this was
the first time Blm was investigated in its native host. Protein secretion in Streptomycetes
is not completely understood and there are alternative mechanisms of secretion that do
not use a signal peptide, which have yet to be elucidated in Streptomycetes (i.e. the ESX-
1 or type VII secretion system) (Mellado et al. 2011; Anne et al. 2014). As a result,
determining the cellular location of Blm using western analysis ruled out the possibility
of Blm being secreted by any mechanism.
In addition, CcaR, a cytoplasmic protein, was not detected in the supernatant
fraction and Blip, a secreted protein, was not detected in the cytoplasmic fraction of the
analysis, therefore there was no cross contamination of samples and cell lysis was not a
factor while harvesting the cultures.
Previously hypothesized functions of being a catalytic enzyme acting as either an
esterase on substrates similar to 3’-O- acetyl cephalosporins or an isomerase enabling the
epimerization step of clavaminic acid to CA (Valegard et al. 2013) remain possible as
catalytic enzymes like these might be localized to the cytoplasm.  It is also possible for
Blm to be an intracellular transport protein responsible for binding CA and bringing it to
the membrane where Blm would interact with Orf13, a proposed efflux pump, and CA
would be transported out of the cell.  The co-transcription of blm and orf13 allows both
proteins to be temporally active, therefore this proposed function of Blm gives further
weight to why the blm/orf13 overlap is present and maintained in homologous CA gene
clusters.  Blm also has the potential to be a CA regulator that controls the expression of
downstream genes involved in the “late” steps of CA production.  Although Blm does not
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appear to possess any DNA binding domains, it is possible that Blm binds to and activates
another protein responsible for CA production.  This other mystery protein could be a
protein previously identified as essential to CA production, such as orf13, orf14, orf15,
orf16, or orf17 (Jensen et al. 2004) and without its activation, CA is not produced.
It has been suggested that the post-translation modification of Blm is possible,
such as Valegard et al. (2013) when they refer to the separation of the N and C termini
through proteolysis.  The separation of the termini is not congruent with the findings in
this study.  According to our western analysis, only a single band representing the full
weight (~50 kDa) of the protein appears on the membrane in the Blm lane in the
cytoplasmic fraction (Figure 3.7 B).  If the termini were separated, there would be either
only one smaller band (< 50 kDa) or two (one full weight 50 kDa) and one smaller (<50
kDa) bands would appear.  Since the FLAG tag is present on the C-terminus, this would
be the only terminus that would be detected during western analysis besides the full
length protein.  Nevertheless, only one full weight band is present after western analysis,
therefore there is no evidence of post-translational proteolysis of Blm under the
conditions of these assays.
4.5: Conclusions
This work elucidated some general attributes of blm and the Blm protein.  Firstly,
all of the blm mutants analyzed to date do not display polar genetic effects, as they all can
be complemented to restore CA production.  Secondly, the Blm-like proteins from the
non-CA producing organisms S. flavogriseus and S. viridis cannot complement the S.
clavuligerus Δblm-INF mutant.  Lastly, Blm was determined to be a cytoplasmic protein
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that lacks post translational modification via proteolysis.  Despite these accomplishments,
there are still more questions to be answered concerning the function of this protein and
how it fits into the late steps of CA production.  In particular, this study bares the question
of exactly where in the cytoplasm Blm is active.  More specific cellular fractions can be
generated and tested to narrow down the exact cytoplasmic location.  It may be possible
for Blm to be present in more than one fraction.  For example, if Blm functions as an
intracellular CA transport protein, it would be found in not only the cytoplasmic fraction
but also the membrane fraction if it was interacting with membrane proteins to excrete
CA out of the cell.  Another question that is not known is if there are partner proteins
interacting with Blm and when are they active?  Answering both of these questions would
narrow the functional possibilities of Blm.  Continued examination of the late genes in
CA biosynthesis will provide better understanding of how the conversion of clavaminic
acid to CA takes place.  More specifically, how the epimerization step takes place and
what proteins are involved.  If Blm plays a role in epimerization, we can engineer Blm to
produce novel molecules that have 5R stereochemistry from 5S molecules.  These novel
molecules may hold the potential for antibiotic activity and aid in the fight against
antibiotic resistance.
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Appendix A- Supplementary data and sequences
Supplementary Figure 1: The sequencing results of the scar region in the Δblm-INF mutant. A) Diagram of the in-frame mutation
of blm present in the S. clavuligerus Δblm-INF mutant. The FRT sites and the scar sequence make up the complete 81 bp scar
sequence. B) The expected nucleotide sequence for the “scar”. C) The nucleotide sequence of the scar region as a result of
Sanger sequencing and the resulting chromatogram.
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Supplementary Figure 2: Standard curve of the peak areas produced by clavulanic acid
standards of known concentration.  The concentrations of clavulanic acid used are: 0.01
μg/μl, 0.13 μg/μl, 0.25 μg/μl, 0.38 μg/μl, and 0.5 μg/μl.  Each standard was prepared in
duplicate (n=2) as described in section 2.6.2.  The peak areas of each were determined
using the Agilent ChemStation software.  From the linear equation, experimental
concentrations were determined for each sample based on the peak area produced.  Error
bars indicate standard error.
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Supplementary Table 1: The dry cell weight (mg) of each replicate used to
determine the clavulanic acid production of each strain used in this study.
Strain Mass (mg)
wt #1 0.6900
wt #2 0.9540
wt +pH #1 0.7710
wt + pH #2 1.1190
wt + pH:blmSC #1 1.9700
wt + pH:blmSC #2 1.2680
Δblm::apraR #1 0.8860
Δblm::apraR #2 0.9220
Δblm::apraR + pHM11a #1 1.3080
Δblm::apraR + pHM11a #2 1.0940
Δblm::apraR + pH:blmSC #1 1.7440
Δblm::apraR + pH:blmSC #2 1.2770
Δorf12::apra #1 1.3880
Δorf12::apra #2 1.4240
Δorf12::apra + pHM11a #1 0.4190
Δorf12::apra + pHM11a #2 0.4290
Δorf12::apra + pH:blmSC #1 0.8600
Δorf12::apra + pH:blmSC #2 1.0530
Δblm-INF # 1 1.6970
Δblm-INF # 2 1.1280
Δblm-INF + pHM11a #1 1.5720
Δblm-INF + pHM11a #2 1.3980
Δblm-INF + pH:blmSC #1 1.2780
Δblm-INF + pH:blmSC #2 1.2700
Δblm-INF + pH:blm-FLAG #1 1.5510
Δblm-INF + pH:blm-FLAG #2 1.2760
Δblm-INF + pH:blmSF #1 1.7540
Δblm-INF + pH:blmSF #2 0.9770
Δblm-INF + pH:blmSV #1 1.7600
Δblm-INF + pH:blmSV #2 1.7780
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Supplementary Figure 3: A comparison of sequencing results (top line) of blm from S.
clavuligerus against the published sequence (bottom line, AY258009).  The forward and
reverse primers (in green), used to amplify blm from S. clavuligerus genomic DNA, are
included as well as the restriction enzyme sites that were used in cloning.
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Supplementary Figure 4: A comparison of sequencing results (top line) of the blm-like
gene from S. viridis against the published sequence (bottom line, CP001683).  The
forward and reverse primers (in green) used to amplify this gene from S. viridis genomic
DNA, are included as well as the restriction enzyme sites used in cloning.
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Supplementary Figure 5: A comparison of sequencing results (top line) of the blm-like
gene from S. flavogriseus against the published sequence (bottom line, CP002475).  The
forward and reverse primers (in green) used to amplify this gene from S. flavogriseus
genomic DNA, are included as well as the restriction enzyme sites used in cloning.  A
point mutation is highlighted at nucleotide position 927.
111
Supplementary Figure 6: A graphical representation of the relative adaptiveness of the amino acid codons used in the
blm-like gene of S. viridis (red) to the codon usage profile of S. clavuligerus (black).  A scale of relative adaptiveness is
along the y-axis.  100 represents the most commonly used codon for each amino acid.  Each amino acid is present on
the x-axis along with its respective codon triplets.  Each bar represents how often that codon is used for that particular
amino acid in each species.  Graph was produced using the Graphical Codon Usage Analyser (Fuhrmann et al. 2004).
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Supplementary Figure 7: A graphical representation of the relative adaptiveness of the amino acid codons used in the
blm-like gene of S. flavogriseus (red) to the codon usage profile of S. clavuligerus (black).  A scale of relative
adaptiveness is along the y-axis.  100 represents the most commonly used codon for each amino acid.  Each amino acid
is present on the x-axis along with its respective codons triplets.  Each bar represents how often that codon is used for
that particular amino acid in each species.  Graph was produced using the Graphical Codon Usage Analyser (Fuhrmann
et al. 2004).
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Supplementary Figure 8: A graphical representation of the relative adaptiveness of the amino acid codons used in blm
of S. clavuligerus (red) to the codon usage profile of S. clavuligerus (black).  A scale of relative adaptiveness is along
the y-axis.  100 represents the most commonly used codon for each amino acid.  Each amino acid is present on the x-
axis along with its respective codons triplets.  Each bar represents how often that codon is used for that particular amino
acid in each species.  Graph was produced using the Graphical Codon Usage Analyser (Fuhrmann et al. 2004).
114
Supplementary Figure 9: A comparison of sequencing results (top line) of blm from S.
clavuligerus against the published sequence (bottom line, AY258009).  The forward and
reverse primers (in green) used to amplify this gene from S. clavuligerus genomic DNA,
are included as well as the restriction enzyme sites used in cloning.  The stop codon is
removed at the end of the FLAG-tagged version, which is noted by the highlighted
nucleotides at the end of the gene.
115
Supplementary Figure 10: A comparison of sequencing results (bottom line) of blip
from S. clavuligerus against the published sequence (top line, M34538).  The forward and
reverse primers (in green) used to amplify this gene from S. clavuligerus genomic DNA,
are included as well as the restriction enzyme sites used in cloning.  The stop codon is
removed at the end of the FLAG-tagged version, which is noted by the highlighted
nucleotides at the end of the gene.
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Supplementary Figure 11: A comparison of sequencing results (top line) of ccaR from
S. clavuligerus against the published sequence (bottom line, AH006362).  The forward
and reverse primers (in green) used to amplify ccaR from S. clavuligerus genomic DNA,
are included as well as the restriction enzyme sites used in cloning.  The stop codon is
removed at the end of the FLAG-tagged version, which is noted by the highlighted
nucleotides at the end of the gene.
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Supplementary Table 2: Peak time (mins) and peak area (mAU*sec) of clavulanic acid peaks
generated through HPLC analysis of derivatized culture supernatants of S. clavuligerus strains
used in this study.
Strain Peak Time (mins) Peak Area (mAU*sec)
WT #1 10.000 2.61333x104
WT #2 10.043 3.27849x104
WT +pH #1 10.008 7295.56592
WT + pH #2 10.046 1.83665 x104
WT + pH:blmSC #1 9.984 1.94081 x104
WT + pH:blmSC #2 10.039 2.03931 x104
Δblm::apraR #1 - -
Δblm::apraR #2 - -
Δblm::apraR + pHM11a #1 - -
Δblm::apraR + pHM11a #2 - -
Δblm::apraR + pH:blmSC #1 9.974 3.01581 x104
Δblm::apraR + pH:blmSC #2 10.084 1.99031 x104
Δorf12::apra #1 - -
Δorf12::apra #2 - -
Δorf12::apra + pHM11a #1 - -
Δorf12::apra + pHM11a #2 - -
Δorf12::apra + pH:blmSC #1 9.970 1.11345 x104
Δorf12::apra + pH:blmSC #2 10.062 1.02468 x104
Δblm-INF # 1 - -
Δblm-INF # 2 - -
Δblm-INF + pHM11a #1 - -
Δblm-INF + pHM11a #2 - -
Δblm-INF + pH:blmSC #1 10.073 7816.24170
Δblm-INF + pH:blmSC #2 10.018 7939.66113
Δblm-INF + pH:blm-flag #1 10.075 3813.06714
Δblm-INF + pH:blm-flag #2 10.022 31439.1064
Δblm-INF + pH:blmSF #1 - -
Δblm-INF + pH:blmSF #2 - -
Δblm-INF + pH:blmSV #1 - -
Δblm-INF + pH:blmSV #2 - -
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Supplementary Figure 12: Standard curve of the distance (Rf) each protein marker of
known molecular weight (log MW) migrated on each western blot in this study.  A line is
generated for each blot (Figure 3.7) using the distance the protein markers ran (Rf) in
comparison to their known molecular weights (log MW) to produce the linear equations
above.  From the linear equations, the experimentally determined weights of the FLAG-
tagged proteins were determined.  Rf = migration distance of the protein/migration -
distance of the dye front.  log MW  is the natural log of the known molecular weight of
each band in each protein ladder. R2 values determine the linearity of the relationship; as
validity increases, the closer the r2 value is to 1.  The molecular weights of each FLAG-
tagged protein determined using this method are displayed in Figure 3.7.
y = -1.1167x + 2.1471
R² = 0.9956
y = -1.1403x + 2.1226
R² = 0.9957
0
0.5
1
1.5
2
0 0.4 0.8 1.2
log
 M
W
Rf
Cytoplasm gel
Supernatant gel
